This invention relates to amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as 3-secretase inhibitors FIELD OF THE INVENTION The present invention relates to amino-5-[substituted-4-(difluoromethoxy) phenyl]-5-phenylimidazolone compounds, which are inhibitors of p-secretase, compositions and kits containing these derivatives, and methods of their preparation and use for the prevention and treatment of diseases or disorders associated with p-Amyloid deposits and neurofibrillary tangles, including Alzheimer's disease, Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), and other neurodegenerative disorders. BACKGROUND ß-Amyloid deposits and neurofibrillary tangles are two major pathologic characterizations associated with Alzheimer's disease (AD). Clinically, AD is characterized by the of loss of memory, cognition, reasoning, judgment, and orientation. Also affected, as the disease progresses, are motor, sensory, and linguistic abilities until global impairment of multiple cognitive functions occurs. These cognitive losses take place gradually, but typically lead to severe impairment and eventual death in 4-12 years. Amyloidogenic plaques and vascular amyloid angiopathy also characterize the brains of patients with Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), and other neurodegenerative disorders. Neurofibrillary tangles also occur in other neurodegenerative disorders including dementia-inducing disorders (Varghese, J., et al, Journal of Medicinal Chemistry, 2003, 46, 4625-4630). P-Amyloid deposits are predominately an aggregate of Aß peptide, which in turn is a product of the proteolysis of amyloid precursor protein (APP). More specifically, Aß peptide results from the cleavage of APP at the C-terminus by one or more y-secretases, and at the N-terminus by p-secretase enzyme (BACE), also known as aspartyl protease, as part of the p-amyloidogenic pathway. BACE activity is correlated directly to the generation of Aß peptide from APP (Sinha, et al, Nature, 1999,402, 537-540), and studies increasingly indicate that the inhibition of BACE inhibits the production of Aß peptide (Roberds, S. L, et al, Human Molecular Genetics, 2001,10,1317-1324). Therefore, it is an object of this invention to provide compounds which are inhibitors of p-secretase and are useful as therapeutic agents in the treatment, prevention or amelioration of a disease or disorder characterized by elevated p-amyloid deposits or p-amyloid levels in a patient. In addition to potent inhibitory BACE activity, a successful drug candidate must pass a myriad of tests associated with toxicity and safety. One such test is the so-called "hERG-test." The hERG (human Ether-a-go-go Related Gene) channel is an important potassium (K) channel responsible for cardiac action potential. Drug interaction with the hERG channel can decrease channel function causing an acquired long QT syndrome and potentially death as a result of heart malfunction. Consequently, hERG-blocking properties will end the prospects of a potential drug. Frustratingly, there is now no way to a priori predict whether or not a particular class of compounds will block hERG channels. Accordingly, it is another object of the invention to provide compounds that do not substantially block hERG channels. It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment, prevention or amelioration of a disease or disorder characterized by elevated p-amyloid deposits or p-amyloid levels in a patient. It is a feature of this invention that the compounds provided may also be useful to further study and elucidate the p-secretase enzyme. These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow. SUMMARY OF THE INVENTION wherein The present invention provides a compound of formula I (FORMULA REMOVED) R1 and R2 are each independently H or an alkyl, cycloalkyi, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atom to which they are attached form an optionally substituted 5- to 7-membered ring optionally interrupted by an additional heteroatom selected from O, N or S; R3 is H or an alkyl, cycloalkyi, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R4, R5 and R6 are each independently H, halogen, NO2, CN, COR9, NR10CO2R11, NR12R13, OR14, NR15COR16, SO„Ri7 or an alkyl, haloalkyi, alkenyl, haloalkenyl, alkynyl, cycloalkyi, alkoxy, alkenyloxy, alkynyloxy or cycloheteroalkyl group each optionally substituted or when attached to adjacent carbon atoms R4 and R5 may be taken together with the atoms to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one or two heteroatoms selected from O, N or S; n is 0,1 or 2; R7 and R8 are each independently H, halogen, NR20R21 or an alkyl, alkenyl, cycloalkyi or alkoxy group each group optionally substituted with the proviso that one of R7 or R8 must be other than H; R9and R17 are each independently H, NR18R19 or an alkyl, haloalkyi, alkoxyalkyl, alkenyl, alkynyl, cycloalkyi or aryl group each optionally substituted; R10 and R15are each independently H or an optionally substituted alkyl group; R11, R14 and R16 are each independently H or an alkyl, haloalkyi, alkoxyalkyl, alkenyl, alkynyl, cycloalkyi or aryl group each optionally substituted; R12 and R13 are each independently H or an alkyl or cycloalkyi group each optionally substituted or R12 and R13 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R18 and R19 are each independently H or an alkyl, alkenyl, alkynyl or cycloalkyi group each optionally substituted or R18 and R19 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R20 and R21 are each independently H, COR22 or an optionally substituted alkyl group; and R22 is an optionally substituted alkyl group; or a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of such compounds for the treatment of ß-amyloid deposits and neurofibrillary tangles. The formula I compounds are particularly useful in treating Alzheimer's disease, cognitive impairment, Down's Syndrome, HCHWA-D, cognitive decline, senile dementia, cerebral amyloid angiopathy, degenerative dementia, or other neurodegenerative disorders. DETAILED DESCRIPTION OF THE INVENTION Alzheimer's disease (AD) is a major degenerative disease of the brain which presents clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability and gradually leads to profound mental deterioration and death. The exact cause of AD is unknown, but increasing evidence indicates that amyloid beta peptide (A-beta) plays a central role in the pathogenesis of the disease. (D. B. Schenk; R. E. Rydel etal, Journal of Medicinal Chemistry, 1995. 21,4141 and D. J. Selkoe, Physiology Review, 2001. 81, 741). Patients with AD exhibit characteristic neuropathological markers such as neuritic plaques (and in ß-amyloid angiopathy, deposits in cerebral blood vessels) as well as neurofibrillary tangles detected in the brain at autopsy. A-beta is a major component of neuritic plaques in AD brains. In addition, ß-amyloid deposits and vascular ß-amyloid angiopathy also characterize individuals with Downs Syndrome, Hereditary Cerebral Hemmorrhage with Amyloidosis of the Dutch type and other neurodegenerative and dementia-inducing disorders. Overexpression of the amyloid precursor protein (APP), altered cleavage of APP to A-beta or a decrease in the clearance of A-beta from a patient's brain may increase the levels of soluble or fibrullar forms of A-beta in the brain. The ß-site APP cleaving enzyme, BACE1, also called memapsin-2 or Asß-2, was identified in 1999 (R. Vassar, B. D. Bennett, etal, Nature, 1999. 402, 537). BACE1 is a membrane-bound aspartic protease with all the known functional properties and characteristics of ß-secretase. Low molecular weight, non-peptide, non-substrate-related inhibitors of BACE1 orß-secretase are earnestly sought both as an aid in the study of the ß-secretase enzyme and as potential therapeutic agents. Co-pending patent application Serial Number 11/526511 discloses amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds which demonstrate BACE activity and which contain a 5-[4-(difluoromethoxy)phenyl] group having no further substitution on the phenyl ring. Surprisingly, it has now been found that the amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds of the invention demonstrate increased inhibition of ß-secretase over those compounds wherein the 4-(difluoromethoxy)phenyl ring is unsubstituted. Additionally, the 5- [substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds, particularly those compounds of the present invention substituted at R7 with an alkyl group, are surprisingly shown to have favorable hERG properties, whereby potential complications associated with blocking hERG channels, and/or a decrease of channel function causing an acquired long QT syndrome are reduced or eliminated. Advantageously, said 5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds of the invention may be used as safe and effective therapeutic agents for the treatment, prevention or amelioration of a disease or disorder characterized by elevated B-amyloid deposits or ß-amyloid levels in a patient. Accordingly, the present invention provides an amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I (Formula Removed) wherein R1 and R2 are each independently H or an alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atom to which they are attached form an optionally substituted 5- to 7-membered ring optionally interrupted by an additional heteroatom selected from O, N or S; R3 is H or an alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R4, R5 and R6 are each independently H, halogen, N02, CN, COR9, NR10CO2R11, NR12R13. OR14, NR15COR16, SOnRi7 or an alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy or cycloheteroalkyl group each optionally substituted or when attached to adjacent carbon atoms R4 and R5 may be taken together with the atoms to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one or two heteroatoms selected from O, N or S; n is 0,1 or 2; R7 and Re are each independently H, halogen, NR20R21 or an alkyl, alkenyl, cycloalkyi or alkoxy group each group optionally substituted with the proviso that one of R7 or Rs must be other than H; R9and R17 are each independently H, NR18R19 or an alkyl, haloalkyi, alkoxyalkyl, alkenyl, alkynyl, cycloalkyi or aryl group each optionally substituted; R10 and R15 are each independently H or an optionally substituted alkyl group; R11, R14 and R16 are each independently H or an alkyl, haloalkyi, alkoxyalkyl, alkenyl, alkynyl, cycloalkyi or aryl group each optionally substituted; R12 and R13 are each independently H or an alkyl or cycloalkyi group each optionally substituted or R12 and R13 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R18 and R19 are each independently H or an alkyl, alkenyl, alkynyl or cycloalkyi group each optionally substituted or R18 and R19 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S; R20 and R21 are each independently H, COR22 or an optionally substituted alkyl group; and R22 is an optionally substituted alkyl group; or a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. In another embodiment, the compound has the formula IA: (Formula Removed) wherein R11 R2, R3, R4, R5. R6, R7 and R8 are the same as defined for the compound of formula I. In another embodiment, the compound has the formula IB: (Formula Removed) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are the same as defined for the compound of formula I. In another embodiment, if two of R4, R5 and R6 are H, then the other group is not a para -OCHF2 group. In another embodiment, neither R4, R5 nor R6 is a para -OCHF2 group. It is understood that the claims encompass all possible stereoisomers and prodrugs. Moreover, unless stated otherwise, each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyi, cycloheteroalkyi, aryl or heteroaryl group is contemplated as being optionally substituted. An optionally substituted moiety may be substituted with one or more substituents. The substituent groups which are optionally present may be one or more of those customarily employed in the development of pharmaceutical compounds or the modification of such compounds to influence their structure/activity, persistence, absorption, stability or other beneficial property. Specific examples of such substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, aryloxy, amino, alkylamino, dialkylamino, formyl, carbonyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulfinyl, alkylsulfonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, cycloalkyi or cycloheteroalkyi groups, preferably halogen atoms, lower alkyl or lower alkoxy groups, wherein 'lower1 is from 1 to 4 carbon atoms. In one embodiment the substituent groups may be selected from halo, cyano, hydroxy, alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, cycloalkyi, or halo-substituted cycloalkyi. Unless otherwise specified, typically, 0-4 substituents may be present. When any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12 carbon atoms, preferably up to 6 carbon atoms, more preferably up to 4 carbon atoms. Substituent groups that have one or more available hydrogen atoms can in turn optionally bear further independently selected substituents, to a maximum of three levels of substitutions. For example, the term "optionally substituted aryl" is intended to mean an aryl group that can optionaly have up to four of its hydrogen atoms replaced with substituent groups as defined above (i.e., a first level of substitution), wherein each of the substituent groups attached to the aryl group can optionally have up to four of its hydrogen atoms replaced by substituent groups as defined above (i.e., a second level of substitution), and each of the substituent groups of the second level of substitution can optionally have up to four of its hydrogen atoms replaced by substituent groups as defined above (i.e., a third level of substitution). As used herein, the term "alkyl" includes both straight chain and branched-chain (unless defined otherwise) monovalent saturated hydrocarbon moieties of 1-12 carbon atoms, preferably 1-6 carbon atoms (C1-C6 alkyl), more preferably 'lower" alkyl of 1-4 carbon atoms. Examples of saturated hydrocarbon alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologs such as n-pentyl, n-hexyl, and the like. Alkyl groups can be optionally substituted. Suitable alkyl substitutions include, but are not limited to, CN, OH, halogen, alkenyl, alkynyl, cycloalkyl, phenyl, carbamoyl, carbonyl, alkoxy or aryloxy. As used herein the term "haloalkyl" designates a CnH2n+1 group having from one to 2n+1 halogen atoms which may be the same or different. Examples of haloalkyl groups include CF3, CH2CI, C2H3BrCI, C3H5F2, or the like. Similarly, the term haloalkoxy designates an OCnH2n+1 group having from one to 2n+1 halogen atoms which may be the same or different. Preferably the haloalkyl groups are C1-C6 haloalkyl groups. The term "alkoxyalkyl" as used herein, refers to an alkyl group as hereinbefore defined substituted with at least one C1-C4 alkoxy group or C1-C6 alkoxy group. The term "alkenyl", as used herein, refers to either a straight chain or branched-chain hydrocarbon moiety containing at least one double bond and having from 2-12 carbon atoms, preferably 2-6 carbon atoms (C2-C6 alkenyl), more preferably 2-4 carbon atoms. Such hydrocarbon alkenyl moieties may be mono or polyunsaturated, and may exist in the E or Z configurations. The compounds of this invention are meant to include all possible E and Z configurations. Examples of mono or polyunsaturated hydrocarbon alkenyl moieties include, but are not limited to, chemical groups such as vinyl, 2-propenyl, isopropenyl, crotyl, 2-isopentenyl, butadienyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and higher homologs, isomers, or the like. Preferred alkenyl groups are C2-C6 alkenyl. The term "haloalkenyl" as used herein, designates an alkenyl group as defined hereinabove substituted with one or more halogen atoms which may be the same or different. The term "alkynyl", as used herein, refers to an alkyl group having one or more triple carbon-carbon bonds. Alkynyl groups preferably contain 2 to 6 carbon atoms (C2-C6 alkynyl). Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and the like. In some embodiments, alkynyl groups can be substituted with up to four substituent groups, as described hereinabove. Preferred alkynyl groups are C2-C6 alkynyl. The terms "alkoxy", "alkenyloxy" and "alkynyloxy" as used herein, refers to -O-alkyl, -O-alkenyl and -O-alkynyl, respectively, wherein the alkyl, alkenyl and alkynyl groups therein are as defined herein. The term "cycloalkyl", as used herein, refers to a monocyclic, bicyclic, tricyclic, fused, bridged, or spiro saturated carbocyclic moiety of 3-10 carbon atoms (C3-C10 cycloalkyl). Any suitable ring position of the cycloalkyl moiety may be covalently linked to the defined chemical structure. Examples of cycloalkyl moieties include, but are not limited to, chemical groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, adamantyl, spiro[4.5]decanyl, and homologs, isomers, or the like. The term "cycloheteroalkyl" as used herein designates a 5- to 7-membered cycloalkyl ring system containing 1, 2 or 3 heteroatoms, which may be the same or different, selected from N, O or S, and optionally containing one double bond. Exemplary of the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein X, is NR', O or S, and R' is H or an optional substituent as defined hereinabove. (Formula Removed) The term "an/I", as used herein, designates an aromatic carbocyclic moiety of up to 20 carbon atoms, e.g. 6-20 carbon atoms, which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked covalently. Examples of aryl moieties include, but are not limited to, chemical groups such as phenyl, i-naphthyl, 2-naphthyl, dihydronaphthyl, tetrahydronaphthyl, biphenyl, anthryl, phenanthryl, fluorenyl, indanyl, biphenylenyl, acenaphthenyl, acenaphthylenyl, and the like. In ROTO embodiments "aryl" groups can be substituted with from 1-5 subst Preferred aryl groups are C6-C10 aryl. The term "heteroaryl" as used herein designates an aromatic heterocyclic ring system, e.g. having from 5-20 ring atoms, which (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked . , heteroaryl it 15- to 6-membered ring. The rings may contain from one to atoms selected fron; . wherein the nitrogen or are optionally oxidized or nitrogen quaternized. of heteroaryl moieties include, but are not limited such thiophene, pyrrole, pyrarolen imidazole 1H- 1,3,4-oxadiazole. 1,2,4-triazote. , pyridazine, benzoxazole, benzisoxazote, benzpiophene, thianthrene,, benzimidazole, indoto. isoquinoline, quinazeline, quinoxaline, purine, pteridine, 9H-carbazote, d-, or the like. The term "halogen", fluorine, chlorine, bromine, or Iodine. The compounds of the present invention may be converted to salts, in particular pharmaceutically acceptable salts using art recogniszed procedures. Suitable salts with bases are, for example, metal sate, such as alkali or afkaline earth metal salts, for exsrppte sodium, potassium or magnesium salts, of with ammonia or an organic such as morpholine, thiomorphofine, piperidine, pyrrolidine, a mono-, di- or tri- alkylamine, for example 0thyl-iert-butyl-, diethyl-, diisopropyl-, triethyh tributyl- or dimethylpropylamine,, or a mono-, di-, or trihydroxy lower alkylamine, for example mono- triethanolamine. Internal further formed. Salts which are unsuitable for pharmaceutical uses but which can , for example, for the isolation or purification of free compounds or their aceutical!y acceptable salts, are included. The term "pharmaceutically salt", as used herein, refers to derived form organic and inorganic acids such as, for example, acetic, propionic, lactic, citric, tartaric, succinle, fumaric, maleic, malonlic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, mettianesulfonic, napthaienesulfonic, benzenesulfonic, toluenesulfonic. eamphorsuffonic, and similarly known acceptable acids when a compound of this indention contains a basic moiety. Salts may also be formed from etjanic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains a carboxylate or phenolic moiety, or similar moiety capable of forming base addition salts. Compounds of the invention may exist as one or more tautomers. One skilled in the art will recognize that compounds of formula I may also exist as the tautomer It as shown below. Tautomers often exist in equilibrium with each other. As these tautomers interconvert under environmental and physiological conditions, they provide the same useful biological effects. The present invention includes mixtures of such tautomers as well as the individual tautomers. The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Where a stereoisomer is preferred, it may in some embodiments be provided substantially free of the corresponding enantiomer. Thus, an enantiomer substantially free of the corresponding enantiomer refers to a compound that is isolated or separated via separation techniques or prepared free of the corresponding enantiomer. "Substantially free", as used herein, means that the compound is made up of a significantly greater proportion of one steriosomer, preferably less than about 50%, more preferably less than about 75%, and even more preferably less than about 90%. Preferred compounds of formula I are those compounds wherein R1 and R2 are H. Another group of preferred compounds are those compounds of formula I wherein R3 is C1-C4alkyl. More preferably R3 is methyl. Also preferred are those compounds of formula I wherein R4, R5 and R6 are each independently H, halogen, or an alkenyl, alkynyl, alkoxy, alkenyloxy, or alkynyloxy group each optionally substituted. More preferred compounds of the invention are those compounds of formula I wherein R7 is halogen, C1-C4alkyl or C3-C6cycloalkyl. More preferably R7 is halogen, methyl, ethyl, propyl or cyciopropyl. Also more preferred are those compounds wherein R4 is an alkenyl, alkynyl, alkoxy, alkenyloxy, or alkynyloxy group each optionally substituted. Preferably R5 and R6 are each independently H or halogen. Preferably R8 is H or C1-C4alkyl. Also more preferred are those compounds wherein R7 is halogen, C1-C4alkyl or C3-C6cycloalkyl; R1 and R2 are H and R3 is methyl. Another group of more preferred compounds of the invention are those compounds of formula I wherein R7 is halogen, methyl, ethyl, propyl or cyciopropyl; R4 is an alkenyl, alkynyl, alkoxy, alkenyloxy, or alkynyloxy group each optionally substituted; and R5 and R6 are each independently H or halogen. In one embodiment R4 is alkynyl optionally substituted with cycloalkyl. In another embodiment R4 is at the 3-position of the phenyl ring. A further group of more preferred compounds of the invention are those compounds of formula I wherein R1 and R2 are H; R3 is methyl; R4 is an alkenyl, alkynyl, alkoxy, alkenyloxy, or alkynyloxy group each optionally substituted; R5 and R6 are each independently H or halogen; R7 is halogen, methyl, ethyl, propyl or cyciopropyl; and R4 is at the 3-position of the phenyl ring. An addition group of preferred compounds of the invention are those of formula I, wherein R4 is: (Formula Removed) wherein, R23 is selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl, halogen or alkoxyalkyl. More particularly, R23 is methyl, ethyl, cyciopropyl, methoxymethyl, methoxyethyl, propyl, fluoroethyl, fluoromethyl, isopropyl, isobutyl or 1,1-difluoroethyl. In another preferred embodiment, R6 is H and R5 is fluoro substituted at the 4-position of the phenyl ring. Preferred compounds of the invention include: (5R)-2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3- methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro- 4H-imidazol-4-one; 2-Amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-Tiuorophenyl)-1-methyl-1H- imidazol-5(4H )-one; (5S)-2-Amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-fluorophenyl)-1-methyl-1H- imidazol-5(4H)-one; (5R)-2-Amino-4-(4-(difluoromethoxy)-3-methylpheny!)-4-(4-fluorophenyl)-1-methyl-1H- imidazol-5(4H)-one; 2-Amino-5-(3-butoxyphenyl)-5-[3-chloro-4-(difluoromethoxy)-phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[3-(cyclopropylethynyl)phenyl]-5-[4-(difluoro-methoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fIuoro-3-((E)-3- methoxypropenyl)phenyl]-3-methyl-3,5-dihydro-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-((E)-4-fIuorobut-1- enyl)phenyl]-3-methyl-3,5-dihydro-4/V-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-((E)-proß-1-enyl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fIuoro-3-((E)-4-methoxy-but-1- enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-[((E)-3-proß-1-enyl)phenyl]- 3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-((E)-3-methoxyproß-1- enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-((E)-4-fluorobut-1-enyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-((E)-4-methoxybut-1-enyl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-3-methyl-5-[((E)-3-proß-1-enyl)phenyl]- 3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-((E)-3-methoxyproß-1-enyl)- phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl)-5-[3-((E)-4-methoxybut-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl)-5-[3-((E)-4-fluoro-but-1-enyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5,5-bis-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3,5-dimethylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-4-[4-(difluoromethoxy)-3-ethylphenyl]-4-(4-fluorophenyl)-1-methyl-1H-imidazol- 5(4H)-one; 2-Amino-5-[4-(difluoromethoxy)-3-propylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-vinyiphenyl)-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-(trifluoromethyl)phenyl]-3-methyl-5-phenyl-3,5- dihydro-4H-imidazol-4-one; 2-Am i no-5-[4-(difl uoromethoxy)-3-(fluoromethyl )phenyl]-3-methyl-5-phenyl-3,5-di hyd ro- 4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-(fluoromethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro- 4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methoxyphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-fluorophenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-Amino-5-(3-bromophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-(3-bromo-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-methylphenyl)-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 5-{2-Amino-4-[4-(difluoromethoxy)-3-methylphenyl]-1-methyl-5-oxo-4,5-dihydro-1H- imidazol-4-yl}-2-methoxybenzonitrile; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(fluoromethyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-4-[4-(difluoromethoxy)-3-ethylphenyl]-1-methyl-4-phenyl-1H-imidazol- 5(4H)-one; (5R)-2-Amino-4-[4-(difluoromethoxy)-3-ethylphenyl]-1-methyl-4-phenyl-1H-imidazol- 5(4H)-one; (5R)-2-Amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5- dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5- dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-1-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-1-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-Amino-5-(3-bromophenyl)-5-t4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-(3-bromophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-(2-fluoroethoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(3-ethoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-propoxyphenyl)-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoropropoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(3-ethoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-(3-propoxyphenyl)-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[3-(2,2-difluoroethoxy)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-(3-propoxyphenyl)-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoropropoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3- methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-[3-(cyclopropylethynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[3-(cyclopropylethynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3- methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-vinylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-vinylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-methoxyproß-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-methoxyproß-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyproß-1- yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyproß-1- yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyproß-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-methoxyproß-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; or a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. Additional preferred compounds of the present invention include: (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-pent-1-yn-1-ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-pent-1-yn-1-ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-(3-methylphenyl)-3,5-dihydro-4H- imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-(3-pent-1-yn-1-ylphenyl)-3,5- dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-propylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-propylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-(3-but-1-yn-1-ylphenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro- 4H-imidazol-4-one; 2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5R)-2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl}-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3- fluoropropoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3- fluoropropoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-5-{4-fluoro-3-pent-1-yn-1-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-5-[4-fluoro-3-(4-fiuorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(4-fluoro-3-hydroxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(3-ethoxy-4-fluorophenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(4-fluoro-3-propoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amirK>-5-[3-chloro-4^difluoromethoxy)phe^ 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(3-ethoxy-4-fluorophenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylmethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(cyclopropylmethoxy)-4-fluorophenyl]-5-[4-(difIuoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(cyclopropylmethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methyl phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-propoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-propoxyphenyl)-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 3-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-6-fluoro-1 -(2-fluorophenyl)-3,4-dihydro-1 H-2,1 - benzothiazine 2,2-dioxide; 2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(dif!uoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4- fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4- fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol- 4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-hydroxyethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-methoxyethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-amino-5-[3-(2-chloroethylH-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1 -yn-1 -yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl}-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-(3-bromophenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro- 1H-imidazol-4-one; (5R)-2-amino-5-(3-bromophenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5S)-2-amino-5-{3-bromophenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-(3-ethynylphenyl)-3-methyl-3,5-dihydro- 4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-prop-1-yn-1-ylphenyl)-3,5- dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-prop-1-yn-1-ylphenyl)- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-prop-1-yn-1-yl phenyl)- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-(3-but-1-yn-1-ylphenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-pent-1-yn-1-ylphenyl)-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-[3-(3-methylbut-1-yn-1- yl)phenyl]-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-[3-(3-methylbut-1-yn-1- yl)phenyl]-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-[3-(3-methylbut-1-yn-1- yl)phenyl]-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(cyclopropylethynyl)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(cyclopropylethynyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4:(difluoromethoxy)phenyl]-5-[3-(cyclopropylethynyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-hydroxy-3-methylbut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-methoxyprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-methoxybut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-methoxybut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-methoxybut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-methoxypent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-(3-cyclopropylphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-hydroxypent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-hydroxypent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-hydroxypent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-fluoropent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-fluoropent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-fluoropent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5,5-bis[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4- one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fiuoro-3-isopropoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[4-(drfluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3-fIuoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one;and (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; a tautomer thereof; a stereoisomer thereof; or a pharmaceutically acceptable salt thereof. Additional preferred compounds of the present invention include: (Formula Removed) Compounds of formula I may be prepared using conventional synthetic methods and, if required, standard separation or isolation techniques. For example, compounds of formula I may be prepared by reacting a diketone of formula II with an aminoguanidine derivative of formula III in the presence of a base such as a metal carbonate to give the desired formula I compound. The reaction is shown below in flow diagram I. FLOW DIAGRAM I (Formula Removed) Diketone compounds of formula II may be prepared by reacting an alkyne of formula IV with an oxidizing agent such as Pd(ll)CI2/DMSO, N-bromosuccinimide/DMSO, ozone, sodium periodate with ruthenium (IV) oxide hydrate, sulfur trioxide, KMn04, l2/DMSO, or combinations thereof, preferable KMn04 and l2/DMSO. The reaction is shown in flow diagram II. FLOW DIAGRAM II (Formula Removed) Alkyne compounds of formula IV may be prepared by reacting an ethynylbenzene compound of formula V with a substituted-4-(difluoromethoxy)-1-halobenzene compound of formula VI in the presence of a Pd catalyst, such as dichlorobis(triphenylphosphine)palladium (II), and Cul to give the desired phenylethynyl benzene compound of formula IV. The reaction is shown in flow diagram III wherein Hal represents Br or I. FLOW DIAGRAM III (Formula Removed) Advantageously, the compounds of formula I act as BACE inhibitors for the treatment of ß-amyloid deposits and neurofibrillary tangles associated with such diseases as Alzheimer's disease, Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), and other neurodegenerative disorders. Accordingly, the present invention provides methods for modulating BACE and treating, preventing, or ameliorating ß -amyloid deposits and neurofibrillary tangles associated with diseases and disorders such as Alzheimer's disease, Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), or other neurodegenerative disorders. Such methods include providing a patient suffering from or being susceptible to a disease or injury associated with excessive BACE activity an effective amount of a compound of formula I. Also according to the present invention there is provided a method of treating Alzheimer's disease and related senile dementia's in humans or other mammals which comprises administering to a human or other mammal an effective amount of a compound of the present invention. The present invention also provides a method for the treatment of a disorder related to or associated with excessive BACE activity in a patient in need thereof which comprises providing said patient a therapeutically effective amount of at least one compound of formula I. Representative disorders include Alzheimer's disease, cognitive impairment, Down's Syndrome, HCHWA-D, cognitive decline, senile dementia, cerebral amyloid angiopathy, degenerative dementia, or other neurodegenerative disorders. Certain of these diseases are characterized by production of P-amyloid deposits or neurofibrillary tangles. The present invention also provides a method for inhibiting the activity of BACE, comprising administering to a patient or contacting a receptor thereof with an effective amount of at least one compound of formula I. Certain methods further comprise determining BACE activity, either before or after said contacting step. The present invention also provides a method of ameliorating (3-amyloid deposits or neurofibrillary tangles in a mammal which comprises providing said mammal an effective amount of at least one compound of formula I. Also provided are methods of ameliorating symptoms of Alzheimer's disease, cognitive impairment, Down's Syndrome, HCHWA-D, cognitive decline, senile dementia, cerebral amyloid angiopathy, degenerative dementia, or other neurodegenerative disorders in a mammal which comprises providing said mammal an effective amount of at least one compound of formula I. Further methods prevent Alzheimer's disease, cognitive impairment, Down's Syndrome, HCHWA-D, cognitive decline, senile dementia, cerebral amyloid angiopathy, degenerative dementia, or other neurodegenerative disorders in a mammal that is known to suffer from or suspected to be at risk of suffering from such diseases. These methods comprise providing said mammal an effective amount of at least one compound of formula I. As used in accordance with this invention, the term "providing," with respect to providing a compound or substance covered by this invention, means either directly administering such a compound or substance, or administering a prodrug, derivative, or analog which will form the effective amount of the compound or substance within the body. This invention also covers providing the compounds of this invention to treat the disease states disclosed herein that the compounds are useful for treating. The term "patient", as used herein, refers to a mammal, preferably a human. The terms "administer", "administering", or "administration", as used herein, refer to either directly administering a compound or composition to a patient, or administering a prodrug derivative or analog of the compound to the patient, which will form an equivalent amount of the active compound or substance within the patient's body. The terms "effective amount", "therapeutically effective amount" and "effective dosage" as used herein, refer to the amount of a compound that, when administered to a patient, is effective to at least partially ameliorate (and, in preferred embodiments, cure) a condition from which the patient is suspected to suffer. It is understood that the effective dosage of the active compounds of this invention may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the conditbn being treated, as well as the various physical factors related to the individual being treated. For treating Alzheimer's disease and other related senile dementia's, generally, satisfactory results may be obtained when the compounds of this invention are administered to the individual in need at a daily dosage of from about 0.1 mg to about 1 mg per kilogram of body weight, preferably administered in divided doses two to six times per day, or in a sustained release form. For most large mammals, the total daily dosage is from about 3.5 mg to about 140 mg preferably from about 3.5 to about 5 mg. In the case of a 70 kg human adult, the total daily dose will generally be from about 7 mg to about 70 mg and may be adjusted to provide the optimal therapeutic result. This regimen may be adjusted to provide the optimal therapeutic response. In one aspect, the present invention is directed to compositions comprising one or more compounds of formula I and one or more pharmaceutically acceptable carriers. The present invention also comprises pharmaceutical compositions comprising compounds of the above-described formula I and a pharmaceutically acceptable carrier. The term "carrier", as used herein, shall encompass carriers, excipients, and diluents. Examples of carriers are well known to those skilled in the art and are prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference in its entirety. Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable. The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or encapsulating materials. They are formulated in conventional manner, for example, in a manner similar to that used for known antihypertensive agents, diuretics and (3-blocking agents. Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. In powders, the carrier is a finely divided solid, which is an admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidine, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes and ion exchange resins. Preferred surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations herein may utilize standard delay or time-release formulations to alter the absorption of the active compound(s). The oral formulation may also consist of administering the active ingredient in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed. Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration may be in either liquid or solid form. Preferably the pharmaceutical composition is in unit dosage form, e.g, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. Such unit dosage form may contain from about 1 mg/kg to about 250 mg/kg, and may given in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal). When administered for the treatment or inhibition of a particular disease state or disorder, it is understood that the effective dosage may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the condition being treated, as well as the various physical factors related to the individual being treated. In therapeutic application, compounds of the present invention are provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective amount". The dosage to be used in the treatment of a specific case must be subjectively determined by the attending physician. The variables involved include the specific condition and the size, age and response pattern of the patient. In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol. For administration by intranasal or intrabrochial inhalation, the compounds of this invention may be formulated into an aqueous or partially aqueous solution. The compounds of this invention may be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmaceutically acceptable salt may be prepared in water suitably mixed with a surfactant such as hydroxyl-propylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to inhibit the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. The compounds of this invention can be administered transdermal^ through the use of a transdermal patch. For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal). Transdermal administration may be accomplished through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non-toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels and occlusive devices. The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream, such as a semi-permeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature. The compounds of this invention may be administered rectally or vaginally in the form of a conventional suppository. Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used. In certain embodiments, the present invention is directed to prodrugs. Various forms of prodrugs are known in the art, for example, as discussed in, for example, Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al. (ed.), "Design and Application of Prodrugs", Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), Bundgaard, et al., Journal of Drug Deliver reviews, 8:1-38 (1992), Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); and Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975). It is understood that the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subject to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be increased until the desired effects are achieved. For a more clear understanding, and in order to illustrate the invention more clearly, specific examples thereof are set forth hereinbelow. The following examples are merely illustrative and are not to be understood as limiting the scope and underlying principles of the invention in any way. Unless otherwise stated, all parts are parts by weight. The terms DMSO and DMF designate dimethyl sulfoxide and N,N-dimethylformamide, respectively. The terms EtOAc and THF designate ethyl acetate and tetrahydrofuran, respectively. The term NMR designates proton nuclear magnetic resonance and the term MS designates mass spectroscopy with (+) referring to the positive mode which generally gives a M+1 (or M+H) absorption where M = the molecular mass. All compounds are analyzed at least by MS and NMR. EXAMPLE 1 Preparation of 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) Step 1: 1-(difluoromethoxv)-4-iodo-2-methylbenzene A mixture of 4-iodo-2-methylphenol (10 g, 42.7 mmol) in DMF and water was treated with 2-chloro-2,2-difluoroacetic acid (3.61 mL, 42.7 mmol) and potassium carbonate (23.62 g, 171 mmol), heated to 120 °C for 12h, cooled to room temperature and diluted with EtOAc and water. The organic phase was separated, washed sequentially with water and brine, dried over Na2S04 and concentrated in vacuo. The resultant residue was purified by flash chromatography (0-10% EtOAc/hexanes) to give a 1-(difluoromethoxy)-4-iodo-2-methylbenzene (3 g, 10.56 mmol, 24.72% yield) as a clear oil. 1H NMR (400 MHz, DMSO-d6) δ 7.66 (d, J= 1.5 Hz, 1H), 7.56 (dd, J = 8.47 and 2.09 Hz, 1H), 7.15 (t, JH-F = 74 Hz, 1H), 6.92 (d, J = 8.47 Hz, 1H), 2.15 (s, 3H). Step 2: 1-(difluoromethoxv)-2-methyl-4-(phenvlethvnyl)benzene A mixture of 1-(difluoromethoxy)-4-iodo-2-methylbenzene (3 g, 10.56 mmol), ethynylbenzene (1.160 mL, 10.56 mmol), and triethylamine (7.36 mL, 52.8 mmol) in DMF (21.12 mL) was treated with bis(triphenylphosphine)dichloropalladium (0.371 g, 0.528 mmol) and copper(l) iodide (0.201 g, 1.056 mmol), stirred at 25 °C for 2h and partitioned between ether and 1M HCI. The organic phase was separated, washed sequentially with 1M HCI and brine, dried over Na2SO4 and concentrated in vacuo. The resultant residue was purified by flash chromatography (100% hexanes) to providel-(difluoromethoxy)-2-methyl-4-(phenylethynyl)benzene (2.13 g, 8.25 mmol, 78% yield) as a dark brown oil. This oil was used as is in the next step. Step 3: 1-(4-(difluoromethoxv)-3-methylphenvl)-2-phenvlethane-1.2-dione A solution of 1-(difluoromethoxy)-2-methyl-4-(phenylethynyl)benzene (2.13 g, 8.25 mmol) in DMSO was treated with palladium dichlorobisacetonitrile (0.214 g, 0.825 mmol), heated at 145 °C for 1h, allowed to cool to room temperature and partitioned between water and ether. The organic phase was seqarated, washed sequentially with water and brine, dried over Na2S04 and concentrated in vacuo. The resultant residue was purified by flash chromatography (0-20% EtOAc/hexanes) to give 1-(4-(difluoromethoxy)-3-methylphenyl)-2-phenylethane-1,2-dione (2.04 g, 7.03 mmol, 85% yield) as an orange oil that solidified upon standing. MS m/e (M-H)" 289.05 Step 4: 2-Amino-4-(4-(difluoromethoxv)-3-methylDhenyl)-1 -methyl-4-phenvl-1 H-imidazol-5(4H )-one A solution of 1-(4-(difluoromethoxy)-3-methylphenyl)-2-phenylethane-1,2-dione (2. g, 6.89 mmol) in ethanol was treated with sodium carbonate (1.095 g, 10.34 mmol) and 1-methylguanidine hydrochloride (1.132 g, 10.34 mmol), heated to 80 °C, cooled to room temperature and filtered. The filter cake was washed with EtOH. The filtdrates were combined and concentrated in vacuo. The resultant residue was dissolved in CH2CI2 (10 mL) and purified by flash chromatography (0-10% MeOH in CH2CI2) to provide the title product as an off white solid, 2.04 g, 5.91 mmol, 86% yield, identified by NMR and mass spectral analyses. MS m/e (M+H)+ 346.00. EXAMPLE 2 Preparation of (5S)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one [A] and (5R)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one[B] (Formula Removed) A racemic mixture of 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H-imida2ol-4-one (1.8 g, 5.21 mmol) was separated by chiral chromatography (Chiral Cel OJ 5 x 50 cm Mobile phase 15% 2-butanol in hexane (0.1% DEA)) to provide the title product A (S-enantiomer) peak 1, RT = 8.5 min, (0.9 g, 2.61 mmol, 50.0% yield) as a white solid, MS m/e (M+H)+ 346.10, [a]D25 = +11.2 (c = 1 % in MeOH); and the title product B (R-enantiomer) peak 2, RT = 11.8 min, (0.84 g, 2.432 mmol, 46.7% yield) as a white solid, MS m/e (M+H)+346.10, [a]D25 = -9.2 (c = 1% in MeOH). EXAMPLE 3 Preparation of 2-Amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-fluorophenyl)-1 -methyl-1 H-imidazol-5(4H)-one (Formula Removed) Step 1: ([4-(difluoromethoxv)-3-metrivlphenvllethvnvl>trimethylsilane Asolutionof 4-bromo-1-(difluoromethoxy)-2-methylbenzene (5.3 g, 22.36 mmol), ethynyltrimethylsilane (4.74 mL, 33.5 mmol), and triethylamine (15.58 mL, 112 mmol) in DMF was degassed by bubbling with N2 for 30 min, treated with bis(triphen-ylphosphine)dichloropalladium (0.785 g, 1.118 mmol) with continued N2 bubbling, treated with copper(l) iodide (0.426 g, 2.236 mmol), warmed to 65 °C for 12h, cooled toroom temperature, partitioned between ether and 2M HCI and filtered through Celite. The filtrate was separated and the organic phse was washed sequentially with 2M HCI and brine, dried over Na2S04 and concentrated in vacuo. The resultant residue was purified by flash chromatography (100%hexanes) to provide ((4-(difluoromethoxy)-3-methylphenyl)ethynyl)trimethylsilane (5.49 g, 21.58 mmol, 97% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.39 (d, J= 1.5 Hz, 1H), 7.32 (dd, J = 8.47 and 1.5 Hz, 1H), 7.20 (t, JH-F = 74 Hz, 1H), 7.08 (d, J = 8.47 Hz, 1H), 2.15 (s, 3H), 0.18 (s, 9H). Step 2:1-(difluoromethoxy)-4-ethvnvl-2-methylbenzene A solution of ((4-(difluoromethoxy)-3-methylphenyl)ethynyl)trimethylsilane (5.49 g, 21.58 mmol) in CH3OH was treated with potassium carbonate (29.8 g, 216 mmol), stirred for 3h and partitioned between hexanes and water. The organic phase was separated, dried over Na2SO4 and concentrated in vacuo to provide 1-(difluoro-methoxy)-4-ethynyl-2-methylbenzene (2.55 g, 14.00 mmol, 64.9% yield) as a brown oil. 1H NMR (400 MHz, DMSO-d6) δ 7.39 (d, J= 1.4 Hz, 1H), 7.32 (dd, J = 8.46 and 1.1 Hz, 1H), 7.18 (t, JH-F = 74 Hz, 1H), 7.09 (d, J = 8.35 Hz, 1H), 2.16 (s, 3H). Step 3: 1 -(difluoromethoxv)-4-((4-fluorophenvnethvnvlV2-methylbenzene A mixture of 4-fluoro-1-iodobenzene (0.6 g, 2.7 mmol) and l-(difluoro-methoxy)-4-ethynyl-2-methylbenzene (0.74g, 4.05 mmol) is treated with 1 mL of DMF and triethylamine (2.6 mL, 19 mmol), followed by copper iodide (26 mg, 0.14 mmol), bis(triphenylphosphine)dichloropalladium (0.29g, 0.41 mmol) and 2 mL of DMF. The reaction is stirred under nitrogen at room temperature overnight and concentrated under vacuum. The resultant concentrate was purified by flash chromatography (EtOAC: Hexane) to give 1-(difluoromethoxy)-4-((4-fluorophenyl)ethynyl)-2-methylbenzene as an oil (>700mg, 93% yield). Steps 4 and 5: 2-amino-4-(4-(difluoromethoxv)-3-methylphenvlV4-(4-fluorophenvl)-1-methyl-1 H-imidazol-5(4H)-one Using essentially the same procedure described in Example 1, steps 3 and 4 and employing 1-(difluoromethoxy)-4-((4-fluorophenyl)ethynyl)-2-methylbenzene and 1-(difluoromethoxy)-4-iodo-2-methylbenzene, the title product was obtained as a white solid, identified by NMR and mass spectral analyses. MS m/e (M+H)+ 364.3. EXAMPLE 4 Preparation of (5S)-2-Amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-fluorophenyl)-1-methyl-1H-imidazol-5(4H)-one [A] and (5R)-2-Amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-fluorophenyl)-1 -methyl-1 H-imidazol-5(4H)-one [B] (Formula Removed) Using essentially the same procedure described in Example 2 and employing a racemic mixture of 2-amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-fluorophenyl)-1-methyl-1 H-imidazol-5(4H)-one, the title products were obtained and identified by NMR and mass spectral analyses. Title product A (S-enantiomer), MS m/e (M+H)+ 364.3; [α]D25 = +12.9 (c = 1% in MeOH); and title product B (R-enantiomer), MS m/e (M+H)+ 364.3, [α]D25 = -12.0 (c = 1% in MeOH). EXAMPLES 5-22 Preparation of 2-Amino-5-[substituted-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one Compounds (Formula Removed) Using essentially the same procedures described in Examples 1 and 3 employing the appropriate halobenzene and phenylethyne, the compounds shown on Table I were obtained and identified by NMR and mass spectral analyses. TABLE I (Table Removed) [M+H]+ EXAMPLES 23-34 Preparation of 5(S)-2-Amino-5-[substituted-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one and 5(R)-2-Amino-5-[substituted-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one Compounds (Formula Removed) Using essentially the same procedure described in Example 2 and employing the appropriate racemic 2-amino-5-[substituted-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one, the enantiomeric compounds shown in Table II were obtained and identified by NMR and mass spectral analyses. TABLE (Formula Removed) (Table Removed) *1% Methanol Solution ** [M-H]- EXAMPLE 35 Preparation of 2-Amino-5-(3-butoxyphenyl)-5-[3-chloro-4-(difluoromethoxy)-phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) Step 1: 3-((3-Chloro-4-(difluoromethoxy)phenyl)ethynyl)phenol A mixture of bis(triphenylphosphine)dichloropalladiurn(ll) (242 mg, 0.345 mmol), Cul (39 mg, 0.207 mmol), triethylamine (3.49 g, 4.8 mL, 34.5 mmol), and 2-chloro-1-(difluoromethoxy)-4-ethynylbenzene (1.54 g, 7.6 mmol) in DMF was treated with 3-iodophenol (1.52 g, 6.9 mmol), stirred for 3h, diluted with water and extracted with EtOAc. The extracts were combined, washed with water, dried over Na2S04, and concentrated in vacuo to give a residue. The residue was purified by flash chromatography (Si02,1:9 to 3:7 EtOAc:hexanes) to yield 3-((3-chloro-4-(difluoromethoxy)phenyl)ethynyl)phenol as a red oil, 1.55 g, 73% yield, MS (-ESI): m/z 293 ([M-H]). Step 2: 1-(3-Chloro-4-(difluoromethoxv)phenyl)-2-(3-hvdroxvphenyl)ethane-1.2-dione A solution of 3-((3-chloro-4-(difluoromethoxy)phenyl)ethynyl)phenol (1.55 g, 5.25 mmol) in dry DMSO was treated with bis(acetonitrile)dichloropalladium(ll) (135 mg, 0.525 mmol), heated overnight at 145 °C, cooled to room temperature, diluted with water and extracted with EtOAc. The combined extracts were washed with water, dried over Na2S04, and concentrated in vacuo over 5 g Celite. the resultant residue was purified by flash chromatography (Si02,1:9 to 1:4 EtOAc:Hexanes) to give 1-(3-chloro-4-(difluoromethoxy)phenyl)-2-(3-hydroxyphenyl)ethane-1,2-dione as a yellow solid, 1.45 g, 84% yield, MS (+ESI): m/z 327 ([M+H]+). Step 3: 2-Amino-4-(3-chloro-4-(difluoromethoxy)phenyl)-4-(3-hydroxyphenyl)-1 -methyl-1H-imidazol-5(4H)-one A mixture of 1-(3-chloro-4-(difluoromethoxy)phenyl)-2-(3-hydroxyphenyl)ethane-1,2-dione (1.45 g, 4.43 mmol) and 1-methylguanidine (727 mg, 6.65 mmol) in EtOH was treated with Na2CO3 (705 mg, 6.65 mmol), heated at reflux temperature for 1 h, cooled to room temperature and filtered. The filtercake was washed with EtOH, and the combined filtrates were concentrated onto Celite. The resultant residue was purified by flash chromatography (SiO2, DCM to 1:9 MeOH.DCM) to afford 2-amino-4-(3-chloro-4-(difluoromethoxy)phenyl)-4-(3-hydroxyphenyl)-1-methyl-1 H-imidazol-5(4H)-one as a grey foam, 965 mg, 56% yield. Step 4: 2-Amino-4-(3-butoxvphenyl)-4-(3-chloro-4-(difluoromethoxv)phenvn-1 -methyl-1 H-imidazol-5(4H)-one A mixture of 2-amino-4-(3-chloro-4-(difluoromethoxy)phenyl)-4-(3-hydroxyphenyl)-1-methyl-1H-imidazol-5(4H)-one (50 mg, 0.131 mmol) in DMF was treated with Cs2CO3 (43 mg, 0.131 mmol), followed by n-butylbromide (20 mg, 15.4 uL, 0.144 mmol). The mixture was stirred at room temperature overnight, diluted with water and extracted with EtOAc. The combined extracts were dried over Na2S04, and concentrated in vacuo to give an oil. The oil was absorbed onto 250 mg Celite and purified by flash chromatography (Si02, DCM to 1:9 MeOHDCM) to give the title product as a white sticky oil, 25 mg, 43% yield, identified by NMR and mass spectral analyses. MS (+ESI): m/z 438 ([M+Hf) EXAMPLES 36-45 Preparation of 2-Amino-5-(3-alkoxyphenyl)-5-[substituted-4-(difluoromethoxy)-phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one Compounds (Formula Removed) Using essentially the same procedure described in Example 35 and employing the appropriate 2-amino-5-(3-hydroxyphenyl)-5-[substituted-4-(difluoromethoxy)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one compound and desired alkyliodide or alkylbromide, the compounds shown in Table III were obtained and identified by NMR and mass spectral analyses. TABLE (Formula Removed) (Table Removed) EXAMPLE 46 Preparation of 2-Amino-5-[3-(cyclopropylethynyl)phenyl]-5-[4-(difluoro-methoxy)-3-methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) Step 1: 1-(3-(cycloproplyethynyl)phenyl)-2-(4-(difluoromethoxy)-3-methyl- phenyl)ethane-1.2-dione A mixture of 1-(3-bromophenyl)-2-(4-(difluoromethoxy)-3-methylphenyl)-ethane-1,2-dione (1 g, 2.71 mmol), ethynylcyclopropane (0.385 mL, 3.25 mmol), and triethylamine (1.888 mL, 13.54 mmol) in DMF was degassed by bubbling with N2 for 30 min, treated with bis(triphenylphosphine)dichloropalladium (0.095 g, 0.135 mmol), N2 bubbling was continued, then treated with copper(l) iodide (0.052 g, 0.271 mmol), warmed to 65 °C for 2h (reaction was complete by LC/MS), cooled to room temperature and partitioned between ether and 1M HCI. The organic phase was washed sequentially with 1M HCI and brine, dried over Na2SO4 and concentrated in vacuo. The resultant residue was purified by flash chromatography (gradient 0-30% EtOAc:hexanes) to give 1-(3-(cyclopropylethynyl)phenyl)-2-(4-(difluoromethoxy)-3-methylphenyl)ethane-1,2-dione (0.92 g, 2.60 mmol, 96% yield) as an orange solid. MS m/e(M-H)- 353.0 Step 2: 2-amino-4-(3-(cvclopropvlethvnvnphenyl)-4-(4-(difluoromethoxy)-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one A solution of 1-(3-(cyclopropylethynyl)phenyl)-2-(4-(difluoromethoxy)-3-methylphenyl)ethane-1,2-dione (0.92 g, 2.60 mmol) in ethanol was treated with 1-methylguanidine hydrochloride (0.284 g, 2.60 mmol), followed by sodium carbonate (0.275 g, 2.60 mmol), heated to 80 °C for 2h, cooled to room temperature and concentrated in vacuo. The resultant oil residue was purified by flash chromatography (gradient 0-10% MeOH:CH2CI2) to provide the title product as an tan solid, 0.78 g, 1.905 mmol, 73.4% yield, identified by NMR and mass spectral analyses. MS m/e (M-H)" 408.2 EXAMPLES 47 AND 48 Preparation of 2-Amino-5-[3-(alkynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one Compounds (Formula Removed) Using essentially the same the procedure described in Example 46 and employing the appropriate dione and the desired alkyne in step 1, the compounds shown on Table IV were obtained and identified by NMR and mass spectral analyses. TABLE IV (Formula Removed) EXAMPLE 49 Preparation of 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) A mixture of 2-amino-4-(3-bromo-4-fluorophenyl)-4-(4-(difluoromethoxy)-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one (0.75 g, 1.696 mmol), acetonitrile and pyrrolidine was degassed by bubbling through with N2, treated with pent-1-yne (0.251 mL, 2.54 mmol) with continued N2 bubbling, then treated with bis(triphenylphosphine)-dichloropalladium (0.119 g, 0.170 mmol) and copper(l) iodide (0.016 g, 0.085 mmol), heated to 60 °C for 30 min. The reaction mixture was treated with an additional amount of pent-1-yne (0.251 mL, 2.54 mmol), cooled to room temperature and partitioned between EtOAc and saturated NaHCO3. The organic phase was separated, washed with brine, dried over Na2S04 and concentrated in vacuo. The resultant residue was purified by flash chromatography (gradient 0-10% MeOH, CHCI2) to provide the title product as a light colored solid, .635 g, 1.479 mmol, 87% yield, identified by NMR and mass spectral analyses. MS m/e (M+H)+ 430.2 EXAMPLE 50 Preparation of 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1 -yn-1 -yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) Using essentially the same procedure described in Example 49 and employing 2-amino-4-(3-bromo-4-fluorophenyl)-4-(4-(difluoromethoxy)-3-methylphenyl)-1-methyl-1 H-imidazol-5(4H)-one and methyl propargyl ether, the title product was obtained and identified by NMR and mass spectral analyses. EXAMPLES 51-56 Preparation of (5R)-2-Amino-5-[3-(alkynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-oneand(5S)-2-Amino-5-[3-(alkynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one Compounds (Formula Removed) Using essentially the same procedure described in Example 2 and employing the appropriate racemic 2-amino-5-[3-(alkynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one, the enantiomeric compounds shown in Table V were obtained and identified by NMR and mass spectral analyses. TABLE V (Table Removed) EXAMPLE 57 Preparation of 2-Amino-5-(4-difluoromethoxy-3-methylphenyl)-5-[4-fluoro-3-((E)-3-methoxypropenyl)phenyl]-3-methyl-3,5-dihydro-imidazol-4-one (Formula Removed) A degassed solution of 2-amino-5-(3-bromo-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-1H-imidazol-4-one (1 equiv) and 3-methoxypropen-1-ylboronic acid (1.5 equiv) in a 1:1 mixture of 2 M K2CO3 and DME is treated with Pd(CH3CN)2CI2 (0.05 equiv), heated at 95° C for 16h under a nitrogen atmosphere, cooled to room temperature, diluted with water and extracted with CH2CI2. The extracts are combined, washed with brine, dried over Na2SO4 and concentrated in vacuo to afford the title product, identified by NMR and mass spectral analyses. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.63 (dd, 1 H), 7.35 - 7.41 (m, 1 H), 7.25 - 7.35 (m, 2 H), 7.13 (dd, 1 H), 7.03 - 7.10 (m, 1 H), 7.10 (t, 1 H), 6.65 - 6.81 (m, 3 H), 6.25 (dt, 1 H), 4.06 (dd, 2 H), 3.29 (s, 3 H), 2.98 (s, 3 H), 2.18 (s, 3 H) EXAMPLES 58-68 Preparation of 2-Amino-5-[4-(difluoromethoxy)phenyl]-3-methyl-5-(3-substituted-phenyl)-3,5-dihydro-4H-imidazol-4-one Compounds Using essentially the same procedure described in Example 57 and employing the appropriate 2-amino-5-(3-bromophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-1H-imidazol-4-one and desired alkenylboronic acid, the compounds shown below were obtained and identified by NMR and mass spectral analyses. EXAMPLE 58 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-((E)-4-fluorobut-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.62 (dd, 1 H), 7.21 - 7.46 (m, 3 H), 7.12 (dd, 1 H), 7.07 (d, 1 H), 7.10 (t, 1 H), 6.68 (br. s., 2 H), 6.58 (d, 1 H), 6.22 (dt, 1 H), 4.56 (dt, 2 H), 2.98 (s, 3 H), 2.53 - 2.70 (m, 2 H), 2.17 (s, 3 H) EXAMPLE 59: 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-((E)-prop-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.58 (dd, 1 H), 7.22 - 7.38 (m, 3 H), 6.99 - 7.15 (m, 2 H), 7.10 (t, 1 H), 6.66 (br. s., 2 H), 6.46 (dd, 1 H), 6.22 (dq, 1 H), 2.98 (s, 3 H), 2.18 (s, 3H), 1.87 (dd, 3 H) EXAMPLE 60 2-Amino-5-[4-(difiuoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-((E)-4-methoxy-but-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.60 (dd, 1 H), 6.82 - 7.41 (m, 6 H), 6.68 (br. s., 2 H), 6.51 (d, 1 H), 6.21 (dt, 1 H), 3.44 (t, 2 H), 3.25 (s, 3 H), 2.98 (s, 3 H), 2.39 - 2.48 (m, 2H),2.18(s,3H) EXAMPLE 61 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-[((E)-3-prop-1-enyl)phenyl]-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.17 - 7.47 (m, 6 H), 7.06 (d, 1 H), 7.10 (t, 1 H), 6.63 (br. s., 2 H), 6.37 (dd, 1 H), 6.18 (dq, 1 H), 2.98 (s, 3 H), 2.17 (s, 3 H), 1.82 (dd, 3 H) Example 62 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-((E)-3-methoxyprop-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.44 - 7.56 (m, 1 H), 7.17 - 7.44 (m, 5 H), 7.07 (d, 1 H), 7.10 (t, 1 H), 6.64 (br. s., 2 H), 6.56 (d, 1 H), 6.22 (dt, 1 H), 4.02 (dd, 2 H), 3.27 (s, 3H),2.98(s, 3H),2.18(s, 3 H) EXAMPLE 63 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-((E)-4-fluorobut-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.42 - 7.51 (m, 1 H), 7.17 - 7.37 (m, 5 H), 7.07 (d, 1 H), 7.10 (t, 1 H), 6.64 (br. s., 2 H), 6.47 (d, 1 H), 6.17 (dt, 1 H), 4.54 (dt, 2 H), 2.98 (s, 3 H), 2.52 - 2.67 (m, 2 H), 2.17 (s, 3 H) EXAMPLE 64 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-((E)-4-methoxybut-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.39 - 7.46 (m, 1 H), 7.15 - 7.38 (m, 5 H), 7.06 (d, 1H), 7.10 (t, 1 H), 6.66 (s, 2 H), 6.40 (d, 1 H), 6.13 (dt, 1 H), 3.43 (t, 2 H), 3.24 (s, 3 H), 2.98 (s, 3 H), 2.39 (dt, 2 H), 2.17 (s, 3 H) EXAMPLE 65 2-Amino-5-[3-chloro-4-(difiuoromethoxy)phenyl]-3-methyl-5-[((E)-3-prop-1-enyl)phenyl> 3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) δ ppm 7.59 (d, 1 H), 7.48 (dd, 1 H), 6.91 - 7.46 (m, 6 H), 6.77 (br. s., 2 H), 6.38 (dq, 1 H), 6.20 (dq, 1 H), 2.99 (s, 3 H), 1.83 (dd, 3 H) EXAMPLE 66 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-((E)-3-methoxyprop-1-enyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) 1H NMR (300 MHz, DMSO-d6) 6 ppm 7.60 (d, 1 H), 7.49 (dd, 1 H), 6.94 - 7.47 (m, 6 H), 6.78 (br. s., 2 H), 6.57 (d, 1 H), 6.24 (dt, 1 H), 4.02 (dd, 2 H), 3.23 - 3.28 (m, 3 H), 3.00 (s, 3 H) EXAMPLE 67 2-Amino-5-[3-chloro-4-(difluoromethoxy)phenyl)-5-[3-((E)-4-methoxybut-1-enyl)phenyl]-3-methyl-3,580% and the bromide <20% by NMR. Both of these fractions were subjected to flash chromatography (SiO2, hexanes to 5% EtOAc 95% hexanes) to give a combined total of 29.07 g of a red-orange oil. By 1H NMR this oil consisted of a 19:7 mol ratio of the desired product and EtOAc. Actual amount of title compound is 26.6 g, 69%. This material is carried on as is. Step 3:1-(4-(Difluoromethoxy)-3-(2-methoxvethyl)phenyl)-2-phenylethane-1.2-dione This compound was made in a similar manner to Example 95 Step 5 using 1-(difluoromethoxy)-2-(2-methoxyethyl)-4-(phenylethynyl)benzene from the previous step (100 mg, 0.331 mmol), PdCI2(ACN)2 (8.58 mg, 0.033 mmol), and DMSO (1.3 mL) to provide 86 mg, 78%, of the title compound as an orange oil. MS (El): m/z 334 (M+). Step 4: 2-Amino-4-(4-(difluoromethoxy)-3-(2-methoxvethyl)phenyl)-1 -methyl-4-phenyl- 1 H-imidazol-5(4H)-one This compound was made in a similar manner to Example 95 Step 6 using 1-(4-(difluoromethoxy)-3-(2-methoxyethyl)phenyl)-2-phenylethane-1,2-dione from the previous step (85 mg, 0.254 mmol), 1-methylguanidineHCI (42 mg, 0.381 mmol), Na2CO3 (40 mg, 0.381 mmol), and iPrOH (726 uL) to provide 73 mg, 74%, of the title compound as a light yellow foam. MS (+ESI): m/z 390.1 ([M+H]+). EXAMPLE 143 Preparation of: (5S)-2-Amino-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 142 Step 2 was separated by chiral HPLC (Chiralcel OD-H 2 x 25 cm; 20% EtOH in CO2 with NPA additive) to provide the title compound as a beige foam/powder. MS (+ESI): m/z 390.1 ([M+H]+). EXAMPLE 144 Preparation of: (5R)-2-Amino-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 142 Step 2 was separated by chiral HPLC (Chiralcel OD-H 2 x 25 cm; 20% EtOH in CO2 with NPA additive) to provide the title compound as a beige foam/powder. MS (+ESI): m/z 390.1 ([M+H]+). Step 1: ((4-(Difluoromethoxy)-3-isopropvlphenyl)ethynyl)trimethylsilane EXAMPLE 145 Preparation of: 2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) This compound was made in a similar fashion to Example 95 Step 2 using 4-bromo-2-isopropyl(difluoromethoxy)benzene (1.50 g, 5.66 mmol) from Example 137 Step 2, trimethylsilylacetylene (834 mg, 1.20 mL, 8.49 mmol), TEA (2.86 g, 3.95 mL, 28.3 mmol), PdCI2(PPh3)2 (199 mg, 0.283 mmol), Cul (108 mg, 0.566 mmol), and DMF (12.5 mL) to provide 634 mg, 40%, of the title compound as a colorless to light yellow oil. MS (El): m/z 282 (M+). Step 2:1-(Difluoromethoxy)-4-ethynyl-2-isopropvlbenzene This compound was made in a similar manner to Example 95 Step 3 using ((4-(difluoromethoxy)-3-isopropylphenyl)ethynyl)trimethylsilane (630 mg, 2.23 mmol) from the last step, K2CO3 (3.08 g, 22.3 mmol), and MeOH (5.6 mL) to provide 359 mg, 76%, of the title compound as a colorless to light yellow oil. MS (El): m/z 210 (M+). Step 3: 2-Bromo-4-((4-(difluoromethoxy)-3-isopropylphenyl)ethynyl)-1 -fluorobenzene This compound was made in a similar manner to Example 95 Step 2 using 1-(difluoromethoxy)-4-ethynyl-2-isopropylbenzene (350 mg, 1.66 mmol) from the previous step, 3-bromo-4-fluoro-iodobenzene (454 mg, 170 µL, 1.51 mmol), TEA (764 mg, 1.05 mL, 7.55 mmol), PdCI2(PPh3)2 (53 mg, 0.0755 mmol), Cul (8.6 mg, 0.0453 mmol), and DMF (2.3 mL) to provide 433 mg, 75%, of the title compound as a colorless oil. MS (El): m/z 382 (M+). Step 4:1 -(3-Bromo-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-isopropylphenyl)ethane-1.2-dione This compound was made in a similar manner to Example 95 Step 5 using 2-bromo-4-((4-(difluoromethoxy)-3-isopropylphenyl)ethynyl)-1 -fluorobenzene (425 mg, 1.11 mmol) from the previous step, PdCI2(ACN)2 (29 mg, 0.011 mmol), and DMSO (4.5 mL) to provide 365 mg, 79%, of the title compound as a yellow solid. MS (-ESI): m/z413/415 ([M-H]). Step 5:1 -(3-(Cyclopropylethynyl)-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-isopropylphenyl)ethane-1.2-dione This compound was made in a similar manner to Example 102 Step 2 using 1-(3-bromo-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-isopropylphenyl)ethane-1,2-dione (295 mg, 0.710 mmol) from the previous step, cyclopropylacetylene (70 wt% in toluene, 54 mg, 0.817 mmol), TEA (359 mg, 495 µL, 3.55 mmol), PdCI2(PPh3)2 (25 mg, 0.0355 mmol), Cul (13.3 mg, 0.0710 mmol), and DMF (1.6 mL) to provide 156 mg, 55%, of the title compound as an orange oil. The cyclopropylacetylene solution was added after the solution was degassed. MS (+APPI): m/z 401 ([M+H]+). Step6:2-Amino-5-[3-(cvclopropvlethynyl)-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-isopropylphenyll-3-methyl-3.5-dihvdro-4H-imidazol-4-one This compound was made in a similar manner to Example 95 Step 6 using (150 mg, 0.315 mmol) from the previous step, 1-methylguanidine hydrochloride (61 mg, 0.562 mmol), Na2CO3 (60 mg, 0.562 mmol), and EtOH (1.1 mL) to provide 92 mg, 53%, of the title compound as an oily beige foam. MS (+ESI): m/z 456.2 ([M+H]+). EXAMPLE 146 Preparation of: 2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) Step 1:2-Bromo-4-((4-(difluoromethoxy)-3-ethylphenyl)ethynyl)-1-fluorobenzene This compound was made in a similar manner to Example 95 Step 2 using 1-(difluoromethoxy)-2-ethyl-4-ethynylbenzene (2.55 g, 12.95 mmol) from Example 117 Step 4, 3-bromo-4-ftuoro-iodobenzene (3.54 g, 11.77 mmol), TEA (5.96 g, 8.2 mL, 58.85 mmol), PdCI2(PPh3)2 (413 mg, 0.589 mmol), Cul (67 mg, 0.353 mmol), and DMF (18 mL) to provide 3.73 g, 78%, of the title compound as a colorless oil. The reaction mixture was heated for 1.5 h before workup. MS (El): m/z 368 (M+). Step 2:1-(3-Bromo-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-ethylphenyl)ethane-1.2-dione This compound was made in a similar manner to Example 95 Step 5 using 2-Bromo-4-((4-(difluoromethoxy)-3-ethylphenyl)ethynyl)-1-fluorobenzene (3.7 g, 10.0 mmol) from the previous step, PdCI2(ACN)2 (259 mg, 1.0 mmol), and DMSO (40 mL) to provide 3.08 g, 76%, of the title compound as a light yellow solid. 1H NMR 500 MHz (DMSO-d6) δ 1.12 (t, J = 7.54 Hz, 3 H); 2.65 (quartet, J = 7.50 Hz, 2 H); 7.31 (d, J = 8.46 Hz, 1 H); 7.40 (t, J = 66.65 Hz, 1 H); 7.57-7.59 (m, 1 H); 7.82 (dd, J = 2.15 Hz, 8.52 Hz, 1 H); 7.90 (d, J = 2.09 Hz, 1 H); 7.93-7.98 (m, 1 H); 8.23 (dd, J = 2.15 Hz, 6.67 Hz, 1 H) Step3:2-Amino-5-f3-bromo-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-ethylphenyl)-3-methyl-3.5-dihvdro-4H-imidazol-4-one This compound was made in a similar manner to Example 95 Step 6 using 1-(3-bromo-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-ethylphenyl)ethane-1,2-dione (3.08 g, 7.67 mmol), 1-methylguanidineHCI (1.26 g, 11.51 mmol), Na2CO3 (1.22 g, 11.51 mmol), and EtOH (22 mL) to provide 2.45 g, 70%, of the title compound as a yellow foam. MS (+ESI): m/z 456.1 ([M+H]+). Step 4: 2-Amino-5-[3-(cvclopropvlethynyl)-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-ethylphenyl1-3-methyl-3.5-dihvdro-4H-imidazol-4-one A mixture of 2-amino-5-[3-bromo-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (400 mg, 0.877 mmol), acetonitrile (2.1 mL), and pyrrolidine (1.4 mL) was degassed for 20 min with nitrogen then cyclopropylacetylene (70 wt% in toluene, 140 µL, 1.32 mmol), PdCI2(PPh3)2 (0.877 mmol), and Cul (0.0439 mmol) were added. The mixture was heated at 60 °C for 1 h after which an additional amount of cyclopropylacetylene (140 µL, 1.32 mmol) was added and the reasction mixture was cooled to room temperature. Then the mixture was diluted with EtOAc and saturated NaHCO3. The biphasic mixture was shaken in a seporatory funnel. Then the organic layer was separated, washed with brine, dried over Na2S04, filtered, and concentrated over 2 g Celite. Flash chromatography (SiO2, DCM to 92:8 DCM:MeOH) provided 371 mg of an orange solid whose 1H NMR indicates a 2:1 ratio of starting bromide to desired product. This material is resubjected to reaction conditions (0.414 mmol cyclopropylacetylene, 14.3 mg, 0.0276 mmol PdCI2(PPh3)2, 2.6 mg, 0.0138 mmol Cul, 440 µL pyrrolidine, and 900 µL ACN), and rechromatographed as before to provide 314 mg, 81%, of the title compound as an orange foam. MS (+ESI): m/z 442.2 ([M+H]+). EXAMPLE 147 Preparation of: (5R)-2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one The compound from Example 146 Step 4 was separated by chiral HPLC (7% (8/2 MeOH/EtOH) in Hexane with DEA additive) to provide the title compound as a beige foam. MS (+ESI): m/z 442.2 ([M+H]+). EXAMPLE 148 Preparation of: (5S)-2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 146 Step 4 was separated by chiral HPLC (7% (8/2 MeOH/EtOH) in hexane with DEA additive) to provide the title compound as a beige to light yellow foam. MS (+ESI): m/z 442.2 ([M+H]+). EXAMPLE 149 Preparation of: 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) This compound was made in a similar fashion to Example 146 Step 4 using 2-amino-5-[3-bromo-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (400 mg, 0.877 mmol) from Example 146 Step 3, acetonitrile (2.1 mL), pyrrolidine (1.4 mL), PdCI2(PPh3)2 (62 mg, 0.0877 mmol), Cul (8.4 mg, 0.0439 mmol), and 4-methylpent-1-yne (108 mg x 2,145 jxL x 2,1.32 mmol x 2) to provide 375 mg, 93%, of the title compound as a yellow foam. The reaction was heated for 3 h before the additional amount of alkyne was added. MS (+ESI): m/z 458.2 ([M+H]+). EXAMPLE 150 Preparation of: (5R)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 149was separated by chiral HPLC (Chiralcel AD-H 2 x 25 cm; 5% IPA in Hexanes with 0.1% DEA additive) to provide the title compound as a yellow foam. MS (+ESI): m/z 458.2 ([M+H]+). EXAMPLE 151 Preparation of: (5S)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 149 was separated by chiral HPLC (Chiralcel AD-H 2 x 25 cm; 5% IPA in Hexanes with 0.1% DEA additive) to provide the title compound as a yellow foam. MS (+ESI): m/z 458.2 ([M+H]+). EXAMPLE 152 Preparation of: 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) This compound was made in a similar fashion to Example 146 Step 4 using 2-amino-5-[3-bromo-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (400 mg, 0.877 mmol) from Example 146 Step 3, acetonitrile (2.1 mL), pyrrolidine (1.4 mL), PdCI2(PPh3)2 (62 mg, 0.0877 mmol), Cul (8.4 mg, 0.0439 mmol), and propargyl methyl ether (93 mg x 2, 111 uL x 2, 1.32 mmol x 2) to provide 375 mg, 93%, of the title compound as a yellow foam. The reaction was heated for 3 h before the additional amount of alkyne was added then the reaction mixture was heated overnight at 60 °C, cooled to room temperature, and worked up. MS (+ESI): m/z 446.1 ([M+H]+). EXAMPLE 153 Preparation of: 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1 -yn-1 -y I )phenyl]-3-methyl-3,5-d i hyd ro-4H -im idazol-4-one (Formula Removed) This compound was made in a similar fashion to Example 146 Step 4 using 2-amino-5-[3-bromo-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (400 mg, 0.877 mmol) from Example 146 Step 3, acetonitrile (2.1 mL), pyrrolidine (1.4 mL), PdCI2(PPh3)2 (62 mg, 0.0877 mmol), Cul (8.4 mg, 0.0439 mmol), and isopropyl acetylene (90 mg x 2, 1.32 mmol x 2) to provide 375 mg, 93%, of the title compound as a yellow foam. MS (+ESI): m/z 441.1 ([M+H]+). EXAMPLE 154 Preparation of: (5R)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 153 was separated by chiral HPLC (Chiralpak AD-H, 2 x 25 cm; 3% (8/2 MeOH/EtOH) in Hexanes with DEA additive)) to provide the title compound as a white foam. MS(+ESI): m/z 441.1 ([M+H]+). EXAMPLE 155 Preparation of: (5S)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 153 was separated by chiral HPLC (Chiralpak AD-H, 2 x 25 cm; 3% (8/2 MeOH/EtOH) in Hexanes with DEA additive) to provide the title compound as a white foam. MS (+ESI): m/z 441.1 ([M+H]+). EXAMPLE 156 Preparation of: (5R)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one The compound from Example 152 was separated by chiral HPLC (Chiralpak AD-H, 0.46 x 25 cm; 5% IPA in Hexanes with 0.1% DEA additive) to provide the title compound as a light yeltow foam. MS (+ESI): m/z 446.1 ([M+H]+). EXAMPLE 157 Preparation of: (5S)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 152 was separated by chiral HPLC (Chiralpak AD-H, 0.46 x 25 cm; 5% IPA in Hexanes with 0.1% DEA additive) to provide the title compound as a yellow foam. MS (+ESI): m/z 446.1 ([M+H]+). EXAMPLE 158 Preparation of: 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1 -yn-1 -yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one Step 1:4-((3-Bromophenyl)ethynyl)-1-(difluoromethoxy)-2-ethylbenzene This compound was made in a similar fashion to Example 95 Step 2 using 1-(difluoromethoxy)-2-ethyl-4-ethynylbenzene (1.95 g, 9.9 mmol) from the previous step, 3-bromo-1-iodobenzene (2.55 g, 9.0 mmol, 1.15 mL), TEA (4.55 g, 6.27 mL, 45.0 mmol), PdCI2(PPh3)2, (316 mg, 0.45 mmol), Cui (51 mg, 0.27 mmol), and DMF (14 mL) to provide 2.81 g, 88%, of the title compound as a yellow oil. The reaction was worked up after 1 h heating. MS (El): m/z 350 (M+). Step 2:1-(3-Bromophenyl)-2-(4-(difluoromethoxy)-3-ethylphenyl)ethane-1.2-dione This compound was made in a similar manner to Example 95 Step 5 using 4-((3-bromophenyl)ethynyl)-1-(difluoromethoxy)-2-ethylbenzene (2.80 g, 7.97 mmol) from the previous step, PdCI2(ACN)2 (207 mg, 0.797 mmol), and DMSO (32 mL) to provide 2.42 g, 79%, of the title compound as a yellow solid. MS (El): m/z 382 (M+). Step 3:1 -(4-(Difluoromethoxy)-3-ethylphenyl)-2-(3-(3-hvdroxvprop-1 -ynvl)phenyl)ethane-1,2-dione This compound was made in a similar manner to Example 95 using 1-(3-bromophenyl)-2-(4-(difluoromethoxy)-3-ethylphenyl)ethane-1,2-dione (2.4 g, 6.26 mmol) from the previous step, propargyl alcohol (526 mg, 555 pL, 9.39 mmol), TEA (3.17 g, 4.36 mL, 31.3 mmol), PdCI2(PPh3)2 (220 mg, 0.313 mmol), Cul (119 mg, 0.626 mmol), and DMF (9.6 mL) to provide 1.43 g, 63%, of the title compound as an orange oil that solidified upon standing to a light yellow solid. MS (El): m/z 358 (M+). Step 4:1 -(4-(Difluoromethoxy)-3-ethylphenyl)-2-(3-(3-fluoroprop-1 -vnvl)phenyl)ethane-1.2-dione To a cooled (-78 °C) solution of 1-(4-(difluoromethoxy)-3-ethylphenyl)-2-(3-(3-hydroxyprop-1-ynyl)phenyl)ethane-1,2-dione (1.4 g, 3.91 mmol) from the previous step in DCM (20 mL) was added DAST (693 mg, 563 nL, 4.29 mmol). The mixture was warmed to room temperature then diluted and shaken with saturated NaHCC>3. The aqueous layer was separated and extracted once with DCM. The combined organic layers were washed with water and brine, dried over Na2S04, filtered, and concentrated onto 8 g Celite. Flash chromatography (SiO2, 5:95 EtOAc:Hexanes to 15:85 EtOAc:Hexanes) to provide 930 mg, 66%, of the title compound as a yellow solid. MS (El): m/z 360 (M+). Step 5: 2-Amino-5-r4-(difluoromethoxy)-3-ethylphenyll-5-r3-(3-fluoroprop-1 -vn-1 -vl)phenyl)-3-methyl-3.5-dihvdro-4H-imidazol-4-one This compound was made in a similar manner to Example 95 Step 6 using 1-(4-(difluoromethoxy)-3-ethylphenyl)-2-(3-(3-fluoroprop-1 -ynyl)phenyl)ethane-1,2-dione (900 mg, 2.5 mmol) from the previous step, 1-methylguanidineHCI (410 mg, 3.75 mmol), Na2CO3 (397 mg, 3.75 mmol), and 200P EtOH (7.2 mL) to provide 748 mg, 72%, of the title compound as a yellow-green foam. MS (+ESI): m/z 416.1 ([M+H]+). EXAMPLE 159 Preparation of: 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) Step 1:2-Bromo-4-((4-(difluoromethoxy)-3-ethylphenyl)ethynyl)-1-fluorobenzene This compound was made in a similar manner to Example 95 Step 2 using 1-(difluoromethoxy)-2-ethyl-4-ethynylbenzene (1.95 g, 9.9 mmol) from the previous step, 3-bromo-4-fluoro-1-iodobenzene (2. g, 9.0 mmol, 1.08 mL), TEA (4.55 g, 6.27 mL, 45.0 mmol), PdCI2(PPh3)2, (316 mg, 0.45 mmol), Cul (51 mg, 0.27 mmol), and DMF (14 mL) to provide 2.81 g, 84%, of the title compound as a yellow oil. The reaction was worked up after 1 h heating. 1H NMR 500 MHz (CDCl3) δ 1.20 (t, J = 7.59 Hz, 3 H); 2.65 (quartet, 7.53 Hz, 2 H); 6.50 (t, J = 73.84 Hz, 1 H); 7.02 (d, J = 8.34 Hz, 1 H); 7.07 (t, J = 8.46 Hz, 1 H); 7.31 (dd, J = 2.08 Hz, 8.34 Hz, 1 H); 7.38-7.42 (m, 2 H); 7.70 (dd, J = 2.03 Hz, 6.54 Hz, 1 H) Step 2:1-(3-Bromo-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-ethylphenyl)ethane-1.2-dione This compound was made in a similar manner to Example 95 Step 5 using 2-bromo-4-((4-(difluoromethoxy)-3-ethylphenyl)ethynyl)-1-fluorobenzene (2.80 g, 7.58 mmol) from the previous step, PdCI2(ACN)2 (197 mg, 0.758 mmol), and DMSO (30 mL) to provide 1.62 g, 53%, of the product and 762 mg of recovered starting material. The SM was resubjected to reaction conditions (0.206 mmol, 53 mg of the catalyst, and 8 mL DMSO) to provide an additional 550 mg of the prodict for a total of 2.17 g, 71%, of the title compound as a yellow solid. MS (El): m/z 400 (M+). Step 3:1-(4-(Difluoromethoxy)-3-ethylphenyl)-2-(3-(3-hvdroxyprop-1-ynyl)phenyl)ethane-1.2-dione This compound was made in a similar manner to Example 95 Step 2 using 1-(3-bromo-4-fluorophenyl)-2-(4-(difluoromethoxy)-3-ethylphenyl)ethane-1,2-dione (2.1 g, 5.23 mmol) from the previous step, propargyl alcohol (440 mg, 464 (aL, 7.85 mmol), TEA (2.64 g, 3.65 mL, 26.15 mmol), PdCI2(PPh3)2 (183 mg, 0.262 mmol), Cut (100 mg, 0.523 mmol), and DMF (8.0 mL) provided 1.51 g, 76%, of the title compound as a dark orange oil that solidified upon standing to a yellow-orange solid. MS (El): m/z 376 (M+). Step 4:1 -(4-(Difluoromethoxy)-3-ethylphenyl)-2-(3-(3-fluoroprop-1 -ynyl)phenyl)ethane- 1,2-dione This compound was made using 1-(4-(difluoromethoxy)-3-ethylphenyl)-2-(3-(3-hydroxyprop-1-ynyl)phenyl)ethane-1,2-dione (1.48 g, 3.93 mmol) from the previous step, DAST (697 mg, 525 \il, 4.33 mmol), and DCM (20 mL) to provide 1.01 g, 68%, of the title compound as a yellow solid. MS (El): m/z 378 (M+). Step 5: 2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyll-5-r4-fluoro-3-(3-fluoroprop-1-vn-1-yl)phenyl]-3-methyl-3.5-dihvdro-4H-imidazol-4-one This compound was made in a similar manner to Example 95 Step 6 using 1-(4-(Difluoromethoxy)-3-ethylphenyl)-2-(3-(3-fluoroprop-1-ynyl)phenyl)ethane-1,2-dione (1.0 g, 2.64 mmol) from the previous step, 1-methylguanidineHCI (434 mg, 3.97 mmol), Na2CO3 (420 mg, 3.97 mmol), and 200P EtOH (7.6 mL) to provide 762 mg, 66%, of the title compound as a yellow-green foam. MS (+ESI): m/z 434.1 ([M+H]+). EXAMPLE 160 Preparation of: (5R)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1 -yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 158 Step 5 was separated by chiral HPLC (Chiralcel AD-H, 2 x 25 cm; 20% IPA in HFE-7200 with DEA additive) to provide the title compound as a white foam. MS (+ESI): m/z 416.1 ([M+H]+). EXAMPLE 161 Preparation of: (5S)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1 -yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 158 Step 5 was separated by chiral HPLC (Chiralcel AD-H, 2 x 25 cm; 20% IPA in HFE-7200 with DEA additive) to provide the title compound as a white foam. MS (+ESI): m/z 416.1 ([M+H]+). EXAMPLE 162 Preparation of: (5R)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1 -yn-1 -yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 159 Step 5 was separated by chiral HPLC (Chiralcel AD-H, 2 x 25 cm; 6% IPA in Hexanes with DEA additive) to provide the title compound as a white foam. MS (+ESI): m/z 434.1 ([M+H]+). EXAMPLE 163 Preparation of: (5S)-2-Amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1 -yn-1 -yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one (Formula Removed) The compound from Example 159 Step 5 was separated by chiral HPLC (Chiralcel AD-H, 2 x 25 cm; 6% IPA in Hexanes with DEA additive) to provide the title compound as a white foam. MS (+ESI): m/z 434.1 ([M+H]+). EXAMPLE 164: Preparation of 2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (Formula Removed) Step 1: Synthesis of 2-Bromo-4-iodo-phenol [Reference: Jon Clardy in Org.Lett. 2006, 8(19) 4251]. In a 250 ml round bottom flask 4-iodo-phenol (10 gm, 45.4 mmol) was dissolved in methanol (60mL). Bromine (2.55 mL) was added dropwise at 0°C. After 30 minutes sodium thiosulfate solution was added, the reaction mixture was extracted with diethylether, washed with water, dried with sodium sulfate and concentrated onto silica gel. Purification by column chromatography (2:1 hexanes/dichloromethane) yielded 3.24 g and mixed fractions were re-subjected to column chromatography (YAMAZEN W-Prep 2XY using 20-35% dichloromethane in hexanes) to give another 6.50 gm for a total of 9.75 gm (72%). 1H NMR (400 MHz, DMSO-d6) δ ppm 6.73 (d, J=8.3 Hz, 1 H) 7.43 (dd, J=8.6, 2.1 Hz, 1 H) 7.72 (d, J=2.1 Hz, 1 H) 10.47 (s, 1 H). Step 2: Synthesis of 2-Bromo-1-difluoromethoxy-4-iodo-benzene In a 100 mL round bottom flask equipped with a large magnetic egg-shaped stir bar were combined 2-Bromo-4-iodo-phenol (3.45 gm, 11.5 mmol), sodium chlorodifluoroacetate (1.76 gm, 11.5 mmol), and potassium carbonate (6.38 gm, 46.2 mmol) in 10% aqueous dimethylformamide (25 mL). The reaction mixture was immersed in a pre-heated oil bath at 110°C. After 8 hours the crude reaction mixture was partitioned between ethylacetate and water, washed with 1N NaOH, brine and dried with magnesium sulfate. Purification by column chromatography (YAMAZEN W-Prep 2XY using hexanes) yielded 2.68 gm of a low melting white solid (67%). *H NMR (400 MHz, DMSO-d6) δ ppm 7.09 (d, 1 H) 7.23 (t, J=73.02 Hz, 1 H) 7.75 (dd, J=8.6,2.1 Hz, 1 H) 8.05 (d, J=2.1 Hz, 1 H). Step 3: Synthesis of (3-Bromo-4-difluoromethoxy-phenylethynyl)-triisopropyl-silane In a 100 mL round bottom flask were combined 2-Bromo-1-difluoromethoxy-4-iodo-benzene (4.28 gm, 12.2 mmol) and triisopropyl-silyl-acetylene (5.45 mL, 14.4 mmol), in triethylamine (12 mL) and dimethylformamide (24 mL). The contents were chilled in an ice-water bath to 0°C. Cuprous iodide (117 mg, 0.614 mmol) and palladium dichlorobis(triphenyl-phosphine) (432 mg, 0.615 mmol) were added and the mixture stirred at 0°C. After 1 hour the crude reaction mixture was partitioned between diethylether and a saturated solution of ammonium chloride, then washed with a saturated solution of ammonium chloride and dried with sodium sulfate. Purification by column chromatography (YAMAZEN W-Prep 2XY using hexanes) and isolation by concentration of desired fractions by rotary evaporation (bath temperature < 5°C) yielded 4.67 gm of an oil (94%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.05 (s, 21 H) 7.25 - 7.30 (m, 1 H) 7.29 (t, J=72.90 Hz, 1 H) 7.50 (dd, J=8.6, 2.1 Hz, 1 H) 7.77 (d, J=2.1 Hz, 1 H); MS (El) m/z 402 [M+.]. Step 4: Synthesis of (3-Cyclopropyl-4-difluoromethoxy-phenylethynvl)-triisopropyl-silane [Reference: Debra Wallace in Tetra.Lett. 2002, 43(39) 6987]. In a 100 mL round bottom flask equipped with a magnetic stir egg were combined (3-Bromo-4-difluoromethoxy-phenylethynyl)-triisopropyl-silane (1.17 gm, 2.90 mmol), cyclopropylboronic acid (0.500 gm, 5.80 mmol), potassium phosphate (2.16 gm, 10.2 mmol), palladium acetate (32 mg, 0.143 mmol) and tricylclohexyl-phosphine (81 mg, 0.290 mmol) in toluene (13 mL) and water (0.65mL). The reaction mixture was immersed in a pre-heated oil bath at 100°C. After 3 hours add more cyclopropyl boronic acid, Pd, P(cHex)3 and phosphate base and continue heating another three hours. The crude reaction mixture was partitioned between ethylacetate and water, extracted with ethylacetate and dried with magnesium sulfate. Purification by column chromatography, YAMAZEN W-Prep 2XY (0-25% ethylacetate in hexanes) yielded 1.01 gm of an oil (96%). 'H NMR (400 MHz, DMSO-d6) δ ppm 0.69 (q, J=5.2 Hz, 2 H) 0.92 (dq, J=8.5, 2.8 Hz, 2 H) 1.05 (s, 21 H) 2.01 (quin, J=6.8 Hz, 1 H) 6.97 (d, J=2.1 Hz, 1 H) 7.10 (d, J=8.6 Hz, 1 H) 7.22 (t, J=73.89 Hz, 1 H) 7.28 (dd, J=8.4, 2.1 Hz, 1 H); MS (El) m/z 364 [M+.]. Step 5: Synthesis of 2-Cvclopropvl-1-difluoromethoxy-4-ethynyl-benzene A 50 mL round bottom flask was charged with (3-Cyclopropyl-4-difluoromethoxy-phenylethynyl)-triisopropyl-silane (0.525 gm, 1.44 mmol), diluted with tetrahydrofuran (THF, 1 ml), and chilled in an ice-water bath. A 1M solution of tetrabutylammonium fluoride in THF (1.5 mL) was added at 0°C. After 1 hour mixture was diluted with hexanes (30 ml) and washed with water (10 mL). Combined hexane extracts were washed with brine, dried with sodium sulfate, and concentrated to an oil by rotary evaporation 0.225 gm (75%). ]H NMR (400 MHz, DMSO-d6) δ ppm 0.68 (quin, J=3.9 Hz, 2 H) 0.91 (dq, J=8.8, 3.5 Hz, 2 H) 2.01 (dq, J=12.4, 5.1 Hz, 1 H) 4.10 (s, 1 H) 7.01 (d, J=2.1 Hz, 1 H) 7.09 (d, J=8.6 Hz, 1 H) 7.20 (t, J=73.95 Hz, 1 H) 7.28 (dd, J=8.3, 2.1 Hz, 1 H). Step 6: Synthesis of 4-(3-Bromo-phenylethvnyl)-2-cvclopropvl-1-difluoromethoxy-benzene In a 100 mL round bottom flask were combined 3-Bromo-1-iodo-benzene (0.305 gm, 1.08 mmol) and 2-Cyclopropyl-1-difluoromethoxy-4-ethynyl-benzene (0.225 gm, 1.08 mmol), in triethylamine (1 mL) and dimethylformamide (2 mL). The contents were chilled in an ice-water bath to 0°C. Cuprous iodide (10 mg, 0.052 mmol) and palladiumdichlorobis-(triphenylphosphine) (38 mg, 0.054 mmol) were added and the mixture stirred at 0°C. After 2 hours the crude reaction mixture was partitioned between diethylether and a saturated solution of ammonium chloride, then washed with a saturated solution of ammonium chloride and dried with magnesium sulfate. Purification by column chromatography (YAMAZEN W-Prep 2XY using hexanes) yielded 0.287 gm of an oil (75%). ]H NMR (400 MHz, DMSO-d6) δ ppm 0.73 (quin, J=3.2 Hz, 2 H) 0.95 (dq, J=8.7, 3.4 Hz, 2 H) 2.05 (td, J=9.0, 4.3 Hz, 1 H) 7.13 - 7.18 (m, 2 H) 7.26 (t, J=73.83 Hz, 1 H) 7.36 (q. J=8.4 Hz, 2 H) 7.52 (dd, J=7.8,1.0 Hz, 1 H) 7.58 (t, J=1.6 Hz, 1 H) 7.74 (d, J=1.9 Hz, 1 H); MS (El) m/z 362 [M+.]. Step 7: Synthesis of 1-(3-Bromo-phenyl)-2-(3-cyclopropyl-4-difluoromethoxy-phenyl)-ethane-1.2-dione In a 50 ml round bottom flask was added 4-(3-Bromo-phenylethynyl)-2-cyclopropyl-1-difluoromethoxy-benzene (0.228 g, 0.628 mmol) in acetone (5.2 mL) and water (1.8 mL). Sodium carbonate (30 mg, 0.35 mmol) magnesium sulfate (105 mg, 0.87 mmol) and potassium permanganate (225 mg, 11.4 mmol) were added (permanganate added last) at room temperature. After 2 hours the reaction was diluted with hexanes (50 mLs), stirred well for 30 minutes and decanted, add 10% EtOAc/hexanes and stir well and decant (from red gummy residue) repeat combine and concentrate to afford 0.203 gm of an oil (82%). 1H NMR (400 MHz, DMSO-d6) δ ppm 0.71 (quin, J=4.0 Hz, 2 H) 0.98 (dt, J=10.6, 4.3 Hz, 2 H) 2.09 (quin, J=6.9 Hz, 1 H) 7.29 (d, J=8.6 Hz, 1 H) 7.40 (t, J=73.2 Hz, 1 H) 7.53 (t, J=7.9 Hz, 2 H) 7.75 (dd, J=8.6, 2.1 Hz, 1 H) 7.86 (dd, J=6.7,1.6 Hz, 1 H) 7.95 (t, J=5.0 Hz, 1 H) 8.03 (t, J=1.7 Hz, 1 H); MS (El) m/z 394 [M+.] Step 8 Synthesis of 2-Amino-5-(3-bromo-phenyl)-5-(3-cvclopropvl-4-difluoromethoxy- phenyl)-3-methyl-3.5-dihvdro-imidazol-4-one In a 50 ml round bottom flask was dissolved 1-(3-Bromo-phenyl)-2-(3-cyclopropyl-4-difluoromethoxy-phenyl)-ethane-1,2-dione (0.102 g, 0.258 mmol) in isopropanol (9 mL). Methylguanidine hydrochloride (42 mg, 0.383 mmol) was added followed by sodium carbonate (41 mg, 0.387 mmol). The mixture was heated (oil bath 86°C) for 16 hours. The isopropanol was removed by rotary evaporation and the residue was transferred onto silica gel using ethyl acetate. Purification by column chromatography [step gradient; EtOAc then 10% MeOH/EtOAc] afforded an oil. The oil was re-dissolved in diethylether, diluted with hexanes and concentrated, twice to give a white solid, 96 mg (83%) mp 85-87 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 0.48 (quin, J=3.9 Hz, 2 H) 0.92 (dq, J=8.7, 3.4 Hz, 2 H) 1.99 (dt, J=10.7, 5.7 Hz, 1 H) 2.93 (s, 3 H) 6.75 (br. s., 2 H) 7.04 (d, J=2.3 Hz, 2 H) 7.11 (t, J=74.23 Hz, 1 H) 7.21 - 7.29 (m, 2 H) 7.40 (dd, J=8.6,1.6 Hz, 2 H) 7.54 (t, J=1.9 Hz, 1 H); MS (ES) m/z 448.0 [M-H]- EXAMPLE 165 Preparation of (R)-2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (Formula Removed) A racemic mixture of 2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (104 mg) was separated by chiral column chromatography (Chiralpak AD-H, 2 x 25 cm) eluting with 4% methanol/ethanol (8/2 with 0.1% diethylamine) in hexanes to provide peak 1 (RT=10.0 min)(R)-2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (21 mg) as a white foam MS m/e [M+H]+ 450.0, [α]D25 = -9.00 (c=1% in MeOH). EXAMPLE 166 Preparation of: (S)-2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (Formula Removed) A racemic mixture of 2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (104 mg) was separated by chiral column chromatography (Chiralpak AD-H, 2 x 25 cm) eluting with 4% methanol/ethanol (8/2 with 0.1% diethylamine) in hexanes to provide peak 2 (RT=11.2 min)(S)-2-Amino-5-(3-bromo-phenyl)-5-(3-cyclopropyl-4-difluoromethoxy-phenyl)-3-methyl-3,5-dihydro-imidazol-4-one (30 mg) as a white foam MS m/e [M+H]+ 450.0, [α]D25 =+5.00 (c=1% in MeOH) EXAMPLE 167 Preparation of: 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-4-(3-ethynylphenyl)-1 -methyl-1 H-imidazol-5(4H)-one (Formula Removed) Step 1: Synthesis of 1-(3-cvclopropyl-4-(difluoromethoxy)phenyl)-2-(3-((triisopropylsilyl)ethynyl)phenyl)ethane-1.2-dione To a Biotage conical microwave vial (0.5-2.0ml) equipped with a magnetic spin vane was added 1-(3-bromophenyl)-2-(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione (100 mg, 0.253 mmol) in triethylamine (1.2 mL). Copper iodide (10 mg, 0.052 mmol) Tetrakis(triphenylphosphine)palladium (20 mg, 0.017 mmol) and (Triisopropyl-silyl)acetylene (0.17 ml, d=0.813, 0.755 mmol) were added at room temperature. The vial was covered with Teflon septa and secured via a crimped aluminum cap. The reaction was irradiated in a Biotage Initiator microwave at 80°C for 60 minutes (Fixed Hold Time On, Normal absorbance level). The same reaction set-up was repeated. Both runs were combined, diluted with diethylether and washed twice with saturated ammonium chloride solution. The ethereal layer was concentrated and loaded onto silica gel. Purification by chromatography (YAMAZEN W-Prep 2XY) eluting with 0-20% (1:1 dichloromethane - diethylether) in hexanes afforded 0.221 gm of an oil (88%). 1H NMR (400 MHz, DMSO-d6) δ ppm 0.74 (dd, J=5.3,1.9 Hz, 2 H) 1.01 (dddd, J=6.3, 4.5, 4.3, 4.3 Hz, 2 H) 1.05 -1.14 (m, 21 H) 2.12 (ddd, J=8.9, 4.3, 3.9 Hz, 1 H) 7.32 (d, J=8.6 Hz, 1 H) 7.43 (t, J=73.14 Hz, 1 H) 7.57 (d, J=2.1 Hz, 1 H) 7.60 - 7.65 (m, 1 H) 7.78 (dd, J=8.5, 2.2 Hz, 1 H) 7.85 (ddd, J=7.9,1.4,1.2 Hz, 1 H) 7.90 (ddd, J=7.8,1.4,1.4 Hz, 1 H)7.93(t, J=1.5Hz, 1 H) Step 2: Synthesis of 2-amino-4-(3-cvclopropyl-4-(difluoromethoxy)phenyl)-4-(3- ethynylphenyl)-1-methyl-1H-imidazol-5(4H)-one 1-(3-Cyclopropyl-4-(difluoromethoxy)phenyl)-2-(3-((triisopropylsilyl)ethynyl-)phenyl)ethane-1,2-dione (0.220 g, 0.443 mmol) was dissolved tetrahydrofuran (2.0 ml). A 1 molar solution of tetrabutylammonium fluoride in tetrahydrofuran (0.500 ml, 0.500 mmol) was added. Solution browns after 20 minutes. The crude reaction was partitioned between mixture of (hexanes/diethylether)/water. The organic layer was concentrated then dissolved in isopropanol (20 mL). Methylguanidine hydrochloride (71 mg, 0.648 mmol) was added followed by sodium carbonate (70 mg, 0.660 mmol). The mixture was heated (oil bath 86°C) for 16 hours. The isopropanol was removed by rotary evaporation and the residue was transferred onto silica gel using ethyl acetate. Purification by column chromatography [step gradient; 50%EtOAc/hex, then 100% EtOAc] afforded oil. The oil was re-dissolved in diethylether, diluted with hexanes and concentrated, twice to give a white foam, 120 mg (69%); !H NMR (400 MHz, DMSO-d6) δ ppm 0.50 (dd, J=5.3, 1.9 Hz, 2H) 0.88-0.93 (m, 2H) 1.97 - 2.06 (m, 1H) 2.96 (s, 3H) 4.15 (s, 1H) 6.72 (br. s., 2H) 7.07 (d, J=8.3 Hz, 2H) 7.13 (t, J=74.3 Hz 1 H) 7.25 - 7.34 (m, 3 H) 7.39 - 7.45 (m, 1 H) 7.47 (s, 1 H); MS (ES) m/z 396.0 [M+H]+ EXAMPLE 168 Preparation of: 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(prop-1-ynyl)phenyl)-1H-imidazol-5(4H)-one Step 1: Synthesis of 1-(3-cvclopropyl-4-(difluoromethoxy)phenyl)-2-(3-(prop-1-vnvl)phenyl)ethane-1,2-dione (Formula Removed) To a Biotage conical microwave vial (0.5-2.0ml) equipped with a magnetic spin vane was added 1-(3-bromophenyl)-2-(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione (100 mg, 0.253 mmol) in triethylamine (1.2 mL). Copper iodide (10 mg, 0.052 mmol), Tetrakis(triphenylphosphine) palladium (20 mg, 0.017 mmol) and Tributyl-propynyl-stannane (0.270 gm, 0.787 mmol) were added at room temperature. The vial was covered with Teflon septa and secured via a crimped aluminum cap. The reaction was irradiated in a Biotage Initiator microwave at 80°C for 60 minutes (Fixed Hold Time On, Normal absorbance level). The reaction set-up was repeated in another vial with 85% of all reagents. The runs were combined, diluted with diethylether and washed twice with saturated ammonium chloride solution. The ethereal layer was concentrated and loaded onto silica gel. Purification by chromatography (YAMAZEN W-Prep 2XY) eluting with 0-20%% ethyl acetate in hexanes afforded 0.135 gm of an oil (56% based on tributyl tin impurity). 1H NMR (400 MHz, CDCl3) δ ppm 0.71-0.75 (m, 2H) 1.01-1.06 (m, 2 H) 2.03 (s, 3H) 2.13-2.20 (m, 1H) 6.62 (t, J=73.2 Hz, 1 H) 7.14 (d, J=8.6 Hz, 1 H) 7.42 (t, J=7.8 Hz, 1 H) 7.59 (s, 1 H) 7.62 (d, J=6.4 Hz, 1 H) 7.69 (dd, t, J=8.5, 2.3 Hz, 1H) 7.84 (d, J=7.89 Hz, 1 H) 7.91 (s, 1 H); MS (ES) m/z 353.1 [M-H] Step 2: Synthesis of 2-amino-4-(3-cvclopropvl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(prop-1-vnvnphenyl)-1H-imidazol-5(4H)-one 1-(3-Cyclopropyl-4-(difluoromethoxy)phenyl)-2-(3-(prop-1-ynyl)phenyl)ethane-1,2-dione (0.100 g, 0.282 mmol) was dissolved in isopropanol (14 mL). Methylguanidine hydrochloride (46 mg, 0.420 mmol) was added followed by sodium carbonate (45 mg, 0.425 mmol). The mixture was heated (oil bath 86°C) for 16 hours. The isopropanol was removed by rotary evaporation and the residue was transferred onto silica gel using ethyl acetate. Purification by column chromatography [step gradient; 50%EtOAc/hex, 100% EtOAc then 10% MeOH/EtOAc] afforded oil. The oil was re-dissolved in diethylether, diluted with hexanes and concentrated, twice to give a white foam, 89 mg (78%); 1H NMR (400 MHz, DMSO-d6) δ ppm 0.44-0.48 (m, 2 H) 0.88-0.93 (m, 2 H) 1.97 (s, 3H) 1.94-2.02 (m, 1 H) 2.92 (s, 3H) 6.66 (br. s., 2 H) 7.02-7.04 (m, 2 H) 7.09 (t, J=74.30 Hz, 1 H) 7.17 - 7.30 (m, 4 H) 7.34 (s, 1 H); MS (ES) m/z 410.2 [M+H]+ EXAMPLE 169 Preparation of: (S)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(prop-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (Formula Removed) A racemic mixture of 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(prop-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (257 mg) was separated by chiral column chromatography (Chiralpak AD, 5 x 50 cm) eluting with 7% ethanol (with 0.1% diethylamine) in hexanes to provide peak 1 (RT=19.0 min) (S)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl -4-(3-(prop-1 -ynyl)phenyl)-1 H-imidazol-5(4H)-one (78 mg) as a white foam MS m/e [M+H]+ 410.0, [α]D25 = -9.0 (c=1% in MeOH). EXAMPLE 170 Preparation of: (R)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(prop-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (Formula Removed) A racemic mixture of 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(prop-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (257 mg) was separated by chiral column chromatography (Chiralpak AD, 5 x 50 cm) eluting with 7% ethanol (with 0.1% diethylamine) in hexanes to provide peak 2 (RT=22.4 min) (R)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(prop-1 -ynyl)phenyl)-1 H-imidazol-5(4H)-one (80 mg) as a white foam MS m/e [M+H]+ 410.0, [α]D25 = +11.0 (c=1% in MeOH) EXAMPLE 171 Preparation of: 2-amino-4-(3-(but-1-ynyl)phenyl)-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-1 H-imidazol-5(4H)-one (Formula Removed) Step 1: Synthesis of 1-(3-(but-1-vnvl)phenyl)-2-(3-cvclopropvl-4-(difluoromethoxy)phenyl)ethane-1,2-dione To a Biotage conical microwave vial (0.5-2.0ml) equipped with a magnetic spin vane was added 1-(3-bromophenyl)-2-(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione (100 mg, 0.253 mmol) in triethylamine (1.2 mL). Copper iodide (9 mg, 0.047 mmol), Tetrakis(triphenylphosphine) palladium (15 mg, 0.013 mmol) were added at room temperature. The vial was covered with Teflon septa and secured via a crimped aluminum cap then chilled in a dry ice bath. A refrigerated cylinder of But-1-yne (Aldrich Chemical) was fastened to a 10mm ID hose fitted with a luer lock adapter and a 20-gauge needle (to pierce septum of chilled microwave vial). The valve was opened and the cylinder inverted to introduce approximately 1.0 ml of But-1-yne. The microwave vial and its contents were removed from the ice bath and allowed to warm to room temperature. The reaction was irradiated in a Biotage Initiator microwave at 80°C for 60 minutes (30 second pre-stir, Fixed Hold Time On, Normal absorbance level). The same reaction set-up was repeated. The runs were combined, diluted with diethylether and washed twice with saturated ammonium chloride solution. The ethereal layer was concentrated and loaded onto silica gel. Purification by chromatography (YAMAZEN W-Prep 2XY) eluting with 0-20% (1:1 dichloromethane - diethylether) in hexanes afforded 0.138 gm of an oil (74%). !H NMR (400 MHz, CDCI3) δ ppm 0.70-0.74 (m, 2 H) 1.01-1.04 (m, 2 H) 1.20 (t, J=7.4 Hz, 3 H) 2.13-2.17 (m, 1 H) 2.38 (q, J=7.5 Hz, 2 H) 6.60 (t, J=73.14 Hz, 1 H) 7.13 (d, J=8.58 Hz, 1 H) 7.41 (t, J=8.58 Hz, 1 H) 7.58 (s, 1 H) 7.61 -7.70 (m, 2 H) 7.82 (t, J=7.9 Hz, 1 H) 7.91 (s, 1H); MS (ES) m/z 367.1 [M-HT Step 2: Synthesis of 2-amino-4-(3-(but-1-ynyl)phenylV4-(3-cvclopropvl-4-(difluoromethoxy)phenyl-1-methyl-1 H-imidazol-5(4H)-one 1 -(3-(but-1 -ynyl)phenyl)-2-(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione (0.206 g, 0.559 mmol) was dissolved in isopropanol (25 mL). Methylguanidine hydrochloride (95 mg, 0.867 mmol) was added followed by sodium carbonate (94 mg, 0.886 mmol). The mixture was heated (oil bath 86°C) for 16 hours. The isopropanol was removed by rotary evaporation and the residue was transferred onto silica gel using ethyl acetate. Purification by column chromatography [step gradient; 50%EtOAc/hex, 100% EtOAc then 10% MeOH/EtOAc] afforded oil. The oil was re-dissolved in diethylether, diluted with hexanes and concentrated, twice to give a white foam, 78 mg (33%); 1H NMR (400 MHz, DMSO-d6) δ ppm 0.45-0.49 (m, 2 H) 0.89-0.94 (m, 2 H) 1.11 (t, J=7.5 Hz, 3 H) 1.96-2.03 (m, 1 H) 2.36 (t, J=7.5 Hz, 2 H) 2.93 (s, 3H) 6.69 (br. s., 2 H) 7.03-7.05 (m, 2 H) 7.11 (t, J=74.4 Hz, 1 H) 7.18-7.33 (m, 4H) 7.36 (s, 1 H); MS (ES) m/z 424.2 [M+H]+ EXAMPLE 172 Preparation of: 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(pent-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (Formula Removed) Step 1: Synthesis of 1-(3-cvclopropvl-4-(difluoromethoxybhenyl)-2-(3-(pent-1-ynyl)phenyl)ethane-l.2-dione To a Biotage conical microwave vial (0.5-2.0ml) equipped with a magnetic spin vane was added 1-(3-bromophenyl)-2-(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione (100 mg, 0.253 mmol) in triethylamine (1.2 mL). Copper iodide (10 mg, 0.052 mmol), Tetrakis(triphenylphosphine) palladium (20 mg, 0.017 mmol) and Pent-1-yne (1.00, d=0.691,10.1 mmol) were added at room temperature. The vial was covered with Teflon septa and secured via a crimped aluminum cap. The reaction was irradiated in a Biotage Initiator microwave at 80°C for 60 minutes (Fixed Hold Time On, Normal absorbance level). The same reaction set-up was repeated. Both runs were combined, diluted with diethylether and washed twice with saturated ammonium chloride solution. The ethereal layer was concentrated and loaded onto silica gel. Purification by chromatography (YAMAZEN W-Prep 2XY) eluting with 0-20% (1:1 dichloromethane -diethylether) in hexanes afforded 0.174 gm of an oil (90%). *H NMR (400 MHz, DMSO-d6) δ ppm 0.70 (quin, J=4.0 Hz, 2 H) 0.95 (t, J=7.2 Hz, 3 H) 0.97 - 1.00 (m, 2 H) 1.52 (sxt, J=7.2 Hz, 2 H) 2.09 (quin, J=6.8 Hz, 1 H) 2.37 (t, J=7.0 Hz, 2 H) 7.29 (d, J=8.6 Hz, 1 H) 7.39 (t, J=73.25 Hz, 1 H) 7.53 (d, J=2.1 Hz, 1 H) 7.55 - 7.57 (m, 1 H) 7.70 - 7.76 (m, 2 H) 7.78 - 7.84 (m, 2 H); MS (ES) m/z 381.2 [M-Hf Step 2: Synthesis of 2-amino-4-(3-cvclopropvl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(pent-1 -ynvl)phenyl)-1 H-imidazol-5(4H)-one 1-(3-Cyclopropyl-4-(difluoromethoxy)phenyl)-2-(3-(pent-1-ynyl)phenyl)ethane-1,2-dione (0.162 g, 0.424 mmol) was dissolved in isopropanol (20 mL). Methylguanidine hydrochloride (69 mg, 0.630 mmol) was added followed by sodium carbonate (68 mg, 0.641 mmol). The mixture was heated (oil bath 86°C) for 16 hours. The isopropanol was removed by rotary evaporation and the residue was transferred onto silica gel using ethyl acetate. Purification by column chromatography [step gradient; 50%EtOAc/hex, 100% EtOAc then 10% MeOH/EtOAc] afforded oil. The oil was re-dissolved in diethylether, diluted with hexanes and concentrated, twice to give a white foam, 144 mg (78%); 'H NMR (400 MHz, DMSO-cQ 8 ppm 0.44-0.48 (m, 2 H) 0.88-0.95 (m, 5 H) 1.50 (sxt, J=7.3 Hz, 2 H) 1.95-2.02 (m, 1 H) 1.52 (t, J=7.0 Hz, 2 H) 2.92 (s, 3H) 6.67 (br. s., 2 H) 7.02-7.04 (m, 2 H) 7.09 (t, J=74.3 Hz, 1 H) 7.17-7.26 (m, 3 H) 7.31 (d, J=7.4 Hz, 1 H) 7.35 (s, 1 H); MS (ES) m/z 438.2 [M+H]+ EXAMPLE 173 Preparation of: 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(3-methylbut-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (Formula Removed) Step 1: Synthesis of 1-(3-cvclopropyl-4-(difluoromethoxy)phenyl)-2-(3-(3-methylbut-1-vnvl)phenyl)ethane-1.2-dione To a Biotage conical microwave vial (0.5-2.0ml) equipped with a magnetic spin vane was added 1-(3-bromophenyl)-2-(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione (100 mg, 0.253 mmol) in triethylamine (1.2 mL). Copper iodide (9 mg, 0.047 mmol), Tetrakis(triphenylphosphine) palladium (15 mg, 0.013 mmol) were added at room temperature. The vial was covered with Teflon septa and secured via a crimped aluminum cap then chilled in a dry ice bath. A refrigerated cylinder of 3-methyl-but-1-yne (GFS Chemical) was fastened to a 10mm ID hose fitted with a luer lock adapter and a 20-gauge needle (to pierce septum of chilled microwave vial). The valve was opened and the cylinder inverted to introduce approximately 1.0 ml of 3-methyl-but-1-yne. The microwave vial and its contents were removed from the ice bath and allowed to ward to room temperature. The reaction was irradiated in a Biotage Initiator microwave at 80°C for 60 minutes (30 second pre-stir, Fixed Hold Time On, Normal absorbance level). The same reaction set-up was repeated. The runs were combined, diluted with diethylether and washed twice with saturated ammonium chloride solution. The ethereal layer was concentrated and loaded onto silica gel. Purification by chromatography (YAMAZEN W-Prep 2XY) eluting with 0-20% (1:1 dichloromethane - diethylether) in hexanes afforded 0.138 gm of an oil (71%). !H NMR (400 MHz, CDCl3) δ ppm 0.70-0.74 (m, 2H) 1.01-1.06 (m, 2 H) 1.23 (d, J=6.8 Hz, 6H) 2.11-2.18 (m, 1H) 2.74 (dt, J=13.7, 6.9 Hz, 1H) 6.60 (t, J=73.1 Hz, 1 H) 7.13 (d, J=8.5 Hz, 1 H) 7.40 (t, J=7.8 Hz, 1 H) 7.58 (s, 1 H) 7.63 (d, J=6.6 Hz, 1 H) 7.69 (dd, t, J=8.5, 2.2 Hz, 1H) 7.82 (d, J=7.88 Hz, 1 H) 7.91 (s, 1 H); MS (ES) m/z 381.2 [M-H]" Step 2: Synthesis of 2-amino-4-(3-cvclopropvl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(3-methylbut-1 -vnvl)phenylV1 H-imidazol-5(4H)-one 1 -(3-Cyclopropyl-4-(difluoromethoxy)phenyl)-2-(3-(3-methylbut-1 -ynyl)phenyl)ethane-1,2-dione (0.139 g, 0.363 mmol) was dissolved in isopropanol (16 mL). Methylguanidine hydrochloride (59 mg, 0.539 mmol) was added followed by sodium carbonate (58 mg, 0.547 mmol). The mixture was heated (oil bath 86°C) for 16 hours. The isopropanol was removed by rotary evaporation and the residue was transferred onto silica gel using ethyl acetate. Purification by column chromatography [step gradient; 50%EtOAc/hex, 100% EtOAc then 10% MeOH/EtOAc] afforded oil. The oil was re-dissolved in diethylether, diluted with hexanes and concentrated, twice to give a white foam, 124 mg (78%); 'H NMR (400 MHz, DMSO-d6) δ ppm 0.44-0.48 (m, 2 H) 0.88-0.92 (m, 2 H) 1.14 (d, J=6.8 Hz, 6H) 1.94-2.00 (m, 1 H) 2.70-2.77 (m, 1 H) 2.92 (s, 3H) 6.67 (br. s., 2 H) 7.02-7.04 (m, 2 H) 7.09 (t, J=74.30 Hz, 1 H) 7.16 - 7.35 (m, 5 H); MS (ES) m/z 438.2 [M+H]+ EXAMPLE 174 Preparation of: (S)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(3-methylbut-1-ynyl)phenyl)-1 H-imidazol-5(4H)-one (Formula Removed) A racemic mixture of 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(3-methylbut-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (216 mg) was separated by chiral column chromatography (Chiralcel AD-H, 2 x 25 cm) eluting with 5% methanol/ethanol (8/2 with 0.1% diethylamine) in hexanes to provide peak 1 (RT=8.9 min)(S)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(3-methylbut-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (47 mg) as a white foam MS m/e [M+H]+ 438.1, [α]D25 = +31.0 (c=1% in MeOH). EXAMPLE 175 Preparation of: (R)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1 -methyl-4-(3-(3-methylbut-1 -ynyl)phenyl)-1 H-imidazol-5(4H)-one (Formula Removed) A racemic mixture of 2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(3-methylbut-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (216 mg) was separated by chiral column chromatography (Chiralcel AD-H, 2 x 25 cm) eluting with 5% methanol/ethanol (8/2 with 0.1% diethylamine) in hexanes to provide peak 2 (RT=11.2 min)(R)-2-amino-4-(3-cyclopropyl-4-(difluoromethoxy)phenyl)-1-methyl-4-(3-(3-methylbut-1-ynyl)phenyl)-1H-imidazol-5(4H)-one (42 mg) as a white foam MS m/e [M+H]+ 438.1, [3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-[3-(cyclopropylethynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[3-(cyclopropylethynyl)phenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3- methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-vinylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-vinylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazoi-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1- yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1- yn-1-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one;and 2-Amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-methoxyprop-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-pent-1-yn-1-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-pent-1-yn-1-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-(3-methylphenyl)-3,5-dihydro-4H- imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-5-(3-pent-1-yn-1-ylphenyl)-3,5- dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-propylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-propylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-(3-but-1-yn-1-ylphenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5-dihydro- 4H-imidazol-4-one; 2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3-methyl-3,5- dihyd ro-4H-im idazol-4-one; (5R)-2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3- fluoropropoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3- fluoropropoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-5-(4-fluoro-3-pent-1-yn-1-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-(3-but-1-yn-1-yl-4-fluorophenyl)-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-fluoroethyl)phenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-am i no-5-[4-(difluoromethoxy)-3-(2-fluoroethyl )phenyl]-5-[4-fl uoro-3-(4-fl uorobut-1 -yn-1 - yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(4-fluoro-3-hydroxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(3-ethoxy-4-fluorophenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-(4-fluoro-3-propoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-chloro-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(3-ethoxy-4-fluorophenyl)-3-methyl-315- dihydro-4H-imidazol-4-one; 2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylmethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-methylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(cyclopropylmethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3- methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(cyclopropylmethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3- methylphenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difIuoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(2-fluoroethoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-propoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-propoxyphenyl)-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 3-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-6-fluoro-1-(2-fluorophenyl)-3,4-dihydro-1H-2,1- benzothiazine 2,2-dioxide; 2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fIuoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl}-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4- fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(2,2-difluoroethoxy)-4- fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(2,2-difluoroethoxy)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-(2- fluoroethyl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(313-difluoropropoxy)-4-fluorophenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3,3-difluoropropoxy)-4-fluorophenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol- 4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-hydroxyethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino)-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-(2-methoxyethyl)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5S)-2-amino-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro-4H- imidazol-4-one; (5R)-2-amino-5-[3-(2-chloroethyl)-4-(difluoromethoxy)phenyl]-3-methyl-5-phenyl-3,5-dihydro- 4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylethyriyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-isopropylphenyl]-3- methyI-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-(cyclopropylethynyl)-4-fluorophenyl]-5-[4-(difluoromethoxy)-3-ethylphenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(4-methylpent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-am i no-5-[4-(dif luoromethoxy)-3-ethyl phenyl]-5-[4-fl uoro-3-(3-methoxyprop-1 -yn-1 -yl )phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methylbut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-ethylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-(3-bromophenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro- 4H-imidazol-4-one; (5R)-2-amino-5-(3-bromophenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; (5S)-2-amino-5-(3-bromophenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-(3-ethynylphenyl)-3-methyl-3,5-dihydro- 4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-prop-1-yn-1-ylphenyl)-3,5- dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-prop-1-yn-1-ylphenyl)- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-prop-1-yn-1-ylphenyl)- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-(3-but-1-yn-1-ylphenyl)-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-(3-pent-1-yn-1-ylphenyl)-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-[3-(3-methylbut-1-yn-1- yl)phenyl]-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-[3-(3-methylbut-1-yn-1- yl)phenyl]-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-5-[3-(3-methylbut-1-yn-1- yl)phenyl]-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(cyclopropylethynyl)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(cyclopropylethynyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(cyclopropylethynyl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-am i no-5-[3-cyclopropyl-4-(difl uoromethoxy)phenyl]-5-[3-( 3-hyd roxy-3-methyl but-1 -yn-1 - yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-methoxyprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-t3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-methoxyprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-am ino-5-[3-cyclopropyl-4-(difl uoromethoxy)phenyl]-5-[3-(4-methoxybut-1 -yn-1 -yl )phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-methoxybut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-methoxybut-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-methoxypent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-(3-cyclopropylphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-hydroxypent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-hydroxypent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-hydroxypent-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-fluoropent-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-fluoropent-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(5-fluoropent-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5,5-bis[3-cyclopropyl-4-(difluoromethoxy)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4- one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-(4-fluoro-3-isopropoxyphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difIuoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-d i hyd ro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3-methyl- 3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[4-(difluoromethoxy)-3-methylphenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fIuoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(3-fluoroprop-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(4-fluorobut-1-yn-1-yl)phenyl]-3- methyl-3,5-dihydro-4H-imidazol-4-one; (5R)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[3-(3-fluoroprop-1-yn-1-yl)phenyl]- 3-methyl-3,5-dihydro-4H-imidazol-4-one; (5S)-2-amino-5-[3-cyclopropyl-4-(difluoromethoxy)phenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one;and (5R)-2-amino-5-[3-cyclopropyl-4-(difIuoromethoxy)phenyl]-5-[4-fluoro-3-(4-fluorobut-1-yn-1- yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; a tautomer thereof; a stereoisomer thereof; or a pharmaceutically acceptable salt thereof. 16. The compound according to claim 1, selected from the group consisting of: (Formula Removed) 17. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I according to any one of claims 1 to 16. 18. A method for the treatment of a disease or disorder associated with excessive BACE activity in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I according to any one of claims 1 to 16. 19. The method according to claim 18 wherein said disease or disorder is selected from the group consisting of: Alzheimer's disease; cognitive impairment; Down's Syndrome; HCHWA-D; cognitive decline; senile dementia; cerebral amyloid angiopathy; and a neurodegenerative disorder. 20. The method according to claim 18 wherein said disease or disorder is characterized by the production of B-amyloid deposits or neurofibrillary tangles. 21. A method for modulating the activity of BACE which comprises contacting a receptor thereof with an effective amount of a compound according to any one of claims 1 to 14. 22. A method for the treatment of Alzheimer's disease in a patient in need thereof which comprises providing to said patient an effective amount of a compound according to any one of claims 1 to 16. 23. A compound or composition according to any one of claims 1 to 17 for the treatment of a disease or disorder associated with excessive BACE activity. 24. Amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as ß-secretase inhibitors and use thereof substantially such as herein described.